Immunosuppression in malignant melanoma induced by tumor-derived extracellular vesicles by Fleming, Viktor
 
 
 
 
Dissertation 
 
 
 
Submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
Presented by 
M.Sc. Viktor Fleming 
 
Born in Mitschurino, Kazakhstan 
  
Oral examination: 13.12.2018 
 
  
 
 
 
 
 
Immunosuppression in malignant melanoma 
induced by tumor-derived extracellular vesicles 
 
 
 
 
 
 
 
 
 
 
 
 
Referees: 
Prof. Dr. Viktor Umansky 
Prof. Dr. Rienk Offringa 
 
  
 
 
 
Declaration according to § 8 (3) b) and c) of the doctoral degree regulations: 
b) I hereby declare that I have written the submitted dissertation myself and in this process 
have used no other sources or materials than those expressly indicated, 
c) I hereby declare that I have not applied to be examined at any other institution, nor have I 
used the dissertation in this or any other form at any other institution as an examination 
paper, nor submitted it to any other faculty as a dissertation. 
 
Heidelberg, 
      
      Name (Viktor Fleming) 
 
 
 
 
 
The work described in this thesis was started in December 2015 and completed in November 
2018 under the supervision of Prof. Dr. Viktor Umansky at the Research Group “Clinical 
Cooperation Unit Dermato-Oncology“ of the German Cancer Research Center (DKFZ), 
Heidelberg and the University Medical Center Mannheim.
  
 
 
 
 
 
 
This work is dedicated to my family. Their support and 
motivation in testing times was crucial for the success of 
this Ph.D. thesis.  
Furthermore, a special thanks goes to Sarah Kolleth who 
embellished my time as a doctoral student. 
 
Thank you!
Publications 
I 
 
Publications 
Publications: 
Fleming V, Hu X, Weller C, Weber R, , Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, 
Bronte V, Utikal J, Altevogt P, Umansky V. Melanoma extracellular vesicles induce 
immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling (submitted) 
Christopher Groth, Xiaoying Hu, Rebekka Weber, Viktor Fleming, Peter Altevogt, Jochen 
Utikal, Viktor Umansky. Immunosuppression mediated by myeloid-derived suppressor cells 
(MDSCs) during tumour progression. Br J Cancer (accepted) 
Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj M, Sulsenti R, Vergani E et 
al. miRNAs delivered by tumor extracellular vesicles induce myeloid suppressor cells in 
melanoma patients and predict resistance to immunotherapy J of Clin Invest 2018 Sep 
Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloid-
derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. 
Front. Immunol.  2018 June  
Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Review: 
Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. 
Front. Immunol.  2018 Mar  
Blattner C*, Fleming V*, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, 
Razon et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in 
melanoma lesions. Cancer Res. 2018 Jan (*equally contributed)  
Fleming V & Umansky V. Editorial: Two MDSC faces in obesity: correcting metabolic 
dysfunctions but promoting tumor development. J of Leukocyte Biology. 2017 Dec  
Sammar M, Siwetz M, Meiri H, Fleming V, Altevogt P, Huppertz B. Expression of CD24 and 
Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal 
interface. Histochem Cell Biol. 2017 May  
Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J. Myeloid-derived 
suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017 
Apr  
Mairhofer DG, Ortner D, Tripp CH, Schaffenrath S, Fleming V, Heger L, Komenda K, Reider 
D, et al. Impaired gp100-specific CD8(+) T-Cell responses in the presence of myeloid-
derived suppressor cells in a spontaneous mouse melanoma model. J Invest Dermatol. 
2015 Nov 
Publications 
II 
 
 
Conference presentations: 
Selected talks: 
06/2018 Keystone Symposia: Exosomes/Microvesicles: Heterogeneity, Biogenesis, 
Function and Therapeutic Developments in Breckenridge, USA 
04/2018 Mye-EUNITER: Myeloid Derived Suppressor Cells: Identification and 
implications in Human Diseases in Crete, Greece 
Poster presentations: 
07/2018 Curious 2018 at Merck KGaA in Darmstadt, Germany 
05/2018 CIMT – The association for cancer immunotherapy in Mainz, Germany 
11/2017 Hallmarks of skin cancer in Heidelberg, Germany 
05/2017 ISEV - International society for extracellular research in Toronto, Canada 
04/2017 CITIM – Cancer immunotherapy & immuno-monitoring in Prague, Czech 
Republic  
05/2016 CIMT – The association for cancer immunotherapy in Mainz, Germany  
Table of Content 
III 
 
Table of Content 
I. Publications ....................................................................................................................... I 
II. Table of Content ..............................................................................................................III 
III. Summary ....................................................................................................................... VII 
IV. Zusammenfassung ....................................................................................................... IX 
1 Introduction ...................................................................................................................... 1 
1.1 Malignant Melanoma .................................................................................................................... 1 
1.1.1 Treatment of MM ................................................................................................................... 2 
1.2 Role of the immune system in cancer ........................................................................................... 4 
1.2.1 Elimination .............................................................................................................................. 5 
1.2.2 Equilibrium ............................................................................................................................. 5 
1.2.3 Escape ..................................................................................................................................... 5 
1.3 Myeloid-derived suppressor cells (MDSC) .................................................................................... 6 
1.3.1 Biology and function of MDSC ................................................................................................ 7 
1.3.2 Immunosuppressive activity of MDSC .................................................................................... 8 
1.4 Programmed death-1 receptor/Programmed death-ligand 1 .................................................... 10 
1.4.1 PD-1 signaling cascade in T cells ........................................................................................... 10 
1.4.2 Regulation of PD-L1 expression ............................................................................................ 11 
1.5 Extracellular Vesicles ................................................................................................................... 12 
1.5.1 EV in cancer progression ...................................................................................................... 13 
1.6 Pathogen Recognition Receptors (PRR) ...................................................................................... 14 
1.6.1 Diversity of Toll-like Receptors (TLR) .................................................................................... 15 
1.6.2 TLR ligands ............................................................................................................................ 16 
1.6.3 TLR signaling ......................................................................................................................... 18 
1.7 Heat-shock proteins .................................................................................................................... 20 
1.7.1 Hsp90 family ......................................................................................................................... 20 
2 Aim of the project ............................................................................................................23 
3 Material and Methods ......................................................................................................24 
3.1 Materials ...................................................................................................................................... 24 
3.1.1 Mouse strains ....................................................................................................................... 24 
3.1.1 Cell lines ................................................................................................................................ 24 
3.1.2 Laboratory equipment.......................................................................................................... 25 
3.1.3 Cell culture products ............................................................................................................ 26 
3.1.4 Cell culture media ................................................................................................................. 27 
3.1.5 Chemicals .............................................................................................................................. 27 
3.1.6 Kits ........................................................................................................................................ 29 
Table of Content 
IV 
 
3.1.7 Antibodies............................................................................................................................. 29 
3.1.8 shRNA ................................................................................................................................... 31 
3.1.8 Primers for mRNA ................................................................................................................. 29 
3.1.8 Primers for miRNA ................................................................................................................ 31 
3.1.9 Cell culture media ................................................................................................................. 31 
3.1.10 Buffers ................................................................................................................................ 32 
3.1.11 Software for data analysis .................................................................................................. 33 
3.2 Methods ...................................................................................................................................... 33 
3.2.1 Isolation of EV ....................................................................................................................... 33 
3.3 Characterization of EV ............................................................................................................. 34 
3.3.1 Nanoparticle tracking analysis .............................................................................................. 34 
3.3.2 Immunogold labeling of Ret-EV ............................................................................................ 35 
3.3.3 MicroRNA microarray ........................................................................................................... 35 
3.3.4 Confocal microscopy ............................................................................................................ 35 
3.3.5 Coupling of EV on latex beads .............................................................................................. 36 
3.3.5.1 Gating of latex beads ......................................................................................................... 36 
3.4 Biochemical methods .................................................................................................................. 37 
3.4.1 Protein isolation ................................................................................................................... 37 
3.4.2 Bicinchoninic-acid assay ....................................................................................................... 38 
3.4.3 SDS-polyacrylamide gel electrophoreses (SDS-PAGE) .......................................................... 38 
3.4.4 Western blot analysis ........................................................................................................... 38 
3.4.5 Immunoblotting .................................................................................................................... 39 
3.4.6 RNA isolaton ......................................................................................................................... 39 
3.4.7 cDNA synthesis ..................................................................................................................... 39 
3.4.8 RT-PCR of mRNA ................................................................................................................... 40 
3.4.9 RT-PCR of mRNA ................................................................................................................... 40 
3.5 Cell culture ................................................................................................................................... 41 
3.5.1 Isolation of IMC .................................................................................................................... 41 
3.5.1.1 Gating of IMC ..................................................................................................................... 42 
3.5.2 EV treatment of IMC ............................................................................................................. 43 
3.5.3 Co-culture studies ................................................................................................................. 43 
3.6 Tissue preparation ....................................................................................................................... 44 
3.6.1 Bone marrow ........................................................................................................................ 44 
3.6.1.1 Gating of BM cells .............................................................................................................. 44 
3.6.2 Tumor ................................................................................................................................... 45 
3.6.2.1 Gating of Tumor ................................................................................................................ 46 
Table of Content 
V 
 
3.7 Spleen ...................................................................................................................................... 46 
3.8 Adult mouse cardiac fibroblast isolation ................................................................................. 47 
3.9 Staining for flow cytometry ..................................................................................................... 47 
3.10 Proliferation assays ............................................................................................................... 48 
3.10.1 Gating of Tumor ................................................................................................................. 49 
3.10.2 Interferon- secretion......................................................................................................... 50 
3.11 Arginase Activity Assay .......................................................................................................... 51 
3.12 Transduction with lentiviral particles .................................................................................... 51 
3.12.1  Alamar blue assay .............................................................................................................. 51 
3.13 Statistics ................................................................................................................................. 52 
4 Results .............................................................................................................................54 
4.1 Characterization of Ret-EVs ......................................................................................................... 54 
4.1.2 Ret-EV are taken up by myeloid cells ....................................................................................... 56 
4.2 Ret-EV alters global miRNA expression in IMC ............................................................................ 57 
4.3 Production of immunosuppressive factors by IMC treated by Ret-EVs ...................................... 59 
4.4 PD-L1 expression on IMC is up regulated after Ret-EV treatment .............................................. 60 
4.4.1 Co-culture of IMC and Ret cells ................................................................................................ 61 
4.4.2 Ret-EV mediated PD-L1 upregulation occurs in vivo ................................................................ 62 
4.5 Ret-EV convert IMC into immunosuppressive cells .................................................................... 64 
4.5 PD-L1 in Ret-EV is not transferred to recipient cells ................................................................... 66 
4.5.1 PD-L1 upregulation is induced by NF-  ................................................................. 67 
4.5.2 TLR agonists induce NF-B activation in myeloid cells ............................................................. 69 
4.5.3 PD-L1 upregulation is induced by MyD88-dependent TLR signaling ....................................... 71 
4.4.6 TLR4 signaling is the main driver for PD-L1 upregulation ........................................................ 72 
4.4.6 Ret-EV educated mice develop tumors faster.......................................................................... 74 
4.5 Ret-EV express high amounts of HSP86 ...................................................................................... 75 
4.5.1 Inhibition of inducible HSP abrogate Ret-EV-mediated PD-L1 induction ................................. 76 
4.5.2 HSP86-deficient Ret cells are unable to induce PD-L1 on IMC ................................................. 78 
4.5.3 Depletion of HSP86 in Ret melanoma cells impairs tumor growth and reduces PD-L1 
expression on MDSC .......................................................................................................................... 79 
5 Discussion .......................................................................................................................81 
5.1 Quality and characteristics of Ret-EV .......................................................................................... 81 
5.2 Expression of PD-L1 on Ret-EV .................................................................................................... 82 
5.3 Ret-EV promote tumor progression by inducing PD-L1 expression on myeloid cell .................. 83 
5.4 Ret-EV promote tumor progression by inducing MDSC .............................................................. 84 
5.5 Myeloid cell predominantly take up tumor-derived EV .............................................................. 86 
Table of Content 
VI 
 
5.6 Tumor-derived EV induce inflammatory pathways in myeloid cells ........................................... 88 
5.7 Tumor-derived EV induce inflammatory pathways in myeloid cells ........................................... 90 
5.8 HSP are drivers of immunosuppression ...................................................................................... 91 
5.9 Conclusion ................................................................................................................................... 92 
6 References .......................................................................................................................93 
7. List of Abbreviations……………………………………………………………………….....110  
8. List of Figures…………………………………………………………………………….....…113     
9. Acknowledgements ...................................................................................................... 109 
 
 
  
Summary 
VII 
 
Summary 
The aim of this project was to investigate the role of tumor-derived extracellular vesicles (EV) 
in the induction of immunosuppression in malignant melanoma. Here, we focused on the 
effect of tumor-derived EV isolated from the Ret murine melanoma model (Ret) on bone 
marrow (BM)-derived immature myeloid cells (IMC). We demonstrated that IMC efficiently 
took up Ret-EV that resulted in the secretion of inflammatory molecules and upregulation of 
miRNA resembling an immunosuppressive phenotype. Furthermore, we found that Ret-EV 
upregulated the expression of PD-L1 on IMC. This PD-L1 expression was induced due the 
TLR signaling pathway, where TLR4 played a dominant role followed by TLR2 and TLR7. 
The TLR signaling led to the activation of NF-B, thereby inducing the transcription of PD-L1. 
Blocking the NF-B pathway diminished the Ret-EV-mediated PD-L1 upregulation on IMC. 
To test whether IMC becomes immunosuppressive upon the treatment with Ret-EV, we 
performed inhibition of T cell proliferation and IFN- secretion assays. Here, we 
demonstrated that IMC became immunosuppressive and converted into MDSC. The 
immunosuppressive activity of Ret-EV-treated IMC was mainly due to the induction of PD-L1. 
By blocking PD-L1 with neutralizing antibodies, we could almost completely abrogate the 
immunosuppressive properties of Ret-EV-treated IMC. Investigating the ligands for this TLR-
dependent upregulation of PD-L1, we found that the inducible heat shock protein (HSP) 86 
was the dominant ligand on Ret-EV, inducing TLR4 signaling in IMC upon Ret-EV treatment. 
Inhibition of all inducible HSP on EV by KNK-437 resulted in the reduction of the Ret-EV 
mediated conversion of IMC into MDSC. Furthermore, we stably knocked-down HSP86 on 
Ret cells. By co-culturing HSP86-deficient Ret cells with IMC, we could not observe a PD-L1 
upregulation, whereas the scramble control showed a strong increase in PD-L1 expression. 
When using DMA to block EV secretion, the EV-mediated PD-L1 upregulation was strongly 
diminished. Finally, we observed an impaired tumor growth of HSP86-deficient Ret cells 
compared to wild type cells in vivo that was accompanied by reduced levels of MDSC 
expressing PD-L1 in the tumor microenvironment (TME).  
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Taken together, our findings demonstrate a critical role in converting IMC into MDSC for 
HSP86 on EV that could be a promising target for immunotherapy. 
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Zusammenfassung 
Das Ziel dieser Arbeit war es den Effekt von extrazellulären Vesikeln des Tumors (EV) auf 
die Induktion der Immunsuppression im Malignen Melanom zu untersuchen. Hierbei 
isolierten wir die EV vom Ret melanoma model. Im Fokus stand der Effekt der EV auf 
myeloide Vorläuferzellen aus dem Knochenmark (IMC). Wir konnten demonstrieren, dass 
IMC die EV internalisierten, was wiederrum zur Ausschüttung von inflammatorischen 
Zytokinen und zur Expression von miRNAs führte, welche mit einem immunsuppressiven 
Phänotyp assoziiert wurden. Des Weiteren konnten wir deutlich darstellen, dass IMC nach 
der Behandlung mit EV PD-L1 hochregulierten. Die PD-L1 Induktion war abhängig vom TLR 
Signalweg, wobei insbesondere TLR4 eine dominante Rolle gespielt hat, gefolgt von TLR2 
und TLR7. Die TLR vermittelte Signalkaskade aktivierte NF-B, was letztendlich zur PD-L1 
Expression führte. Die Blockierung von NF-B unterdrückte die EV-vermittelte 
Hochregulation von PD-L1 auf IMC. Um zu testen, ob die EV-behandelte IMC 
immunsuppressiv wurden, führten wir T Zell Proliferationsexperimente und IFN- Sekretion-
Analysen durch. Hierbei konnten wir beweisen, dass die IMC immunsuppressiv geworden 
sind und dadurch zu MDSC konvertierten. Die Immunsuppression wurde hauptsächlich 
PD-L1 zugeordnet, da durch die Verwendung von PD-L1 neutralisierenden Antikörpern der 
immunsuppressive Effekt verschwand. Auf der Suche nach dem entsprechenden Auslöser 
der TLR-abhängigen Signalkaskade in IMC, fanden wir das induzierbare HSP86 als 
Liganden auf der Oberfläche der EV. Durch die biochemische Inhibierung von HSP86 mit 
KNK-437, konnten wir die TLR-vermittelte Signalkaskade ausschalten und daher auch die 
Konvertierung der IMC zu MDSC unterdrücken. Zusätzlich haben wir die Expression von 
HSP86 permanent mittels shRNA blockiert. Die Ko-Kultivierung von HSP86-Defizienten Ret 
Zellen mit IMC führte zu keiner Hochregulation von PD-L1 auf IMC, wobei hingegen die 
entsprechenden Kontrol-Ret-Zellen eine starke Hochregulation von PD-L1 auf IMC 
induzierten. Die PD-L1 Induktion war EV-vermittelt, da durch die Blockade der EV Sekretion 
mittels DMA die PD-L1 Hochregulierung ausblieb. Letztendlich beobachteten wir ein 
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verlangsamtes Wachstum in vivo von HSP86 defizienten Tumoren, welche mit einer 
Reduktion von PD-L1 auf MDSC im Tumormikromillieu einherging.  
Zusammengefasst demonstrieren wir in dieser Arbeit eine kritische Rolle von HSP86 auf 
Tumor Vesikeln in der Konvertierung von IMC zu MDSC. Somit ist HSP86 ein 
vielversprechender Angriffspunkt für die Immuntherapie.  
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1 Introduction 
1.1  Malignant Melanoma 
Malignant melanoma (MM) is a fast progressing, aggressive and therapy-resistant form of 
skin cancer [1-3]. It arise from melanin-producing melanocytes, which are present at the 
basal layer of the epidermis, inner ear, eyes and leptomeninges [4]. The most frequent type 
of MM is the cutaneous form [3]. The main reason for the malignant transformation of 
melanocytes into neoplastic cells is the accumulation of mutations mainly due to UV 
exposure [5]. Some gene mutations are commonly occurring in MM. The most predominant 
mutation is occurred in the B-rapidly accelerated fibrosarcoma (B-RAF)V600E gene [5]. More 
than 50% of all melanoma patients are bearing this mutation, which leads to the hyper 
activation of this serine/threonine kinase, leading to the constant activation of the mitogen-
activated protein kinase (MAPK) signaling cascade and Rat sarcoma (RAS)-RAF pathway, 
promoting an excessive proliferation of melanocytes [6]. Furthermore, N-RAS mutations are 
found in 15 – 20 % of all melanomas. This type of mutation is associated with an aggressive 
behavior and poor clinical outcome [7].  
During last 50 years, the morbidity of MM increased dramatically [8]. In 1960, the lifetime risk 
to get MM was about 1:600, whereas nowadays it increased up to 1:100 [9]. One explanation 
is the changed lifestyle during the last centuries, whereas people tend to be more outside 
and being scantily dressed. Although, MM accounts only for 1 % of all types of skin cancers, 
it causes about 90 % of all skin cancer-related death [1]. This is due to the resistance to radio 
–and chemotherapies and the aggressive nature of melanoma cells. They rapidly leave the 
dermis and most frequently metastasize into lung, liver, bones and brain [1]. The type of skin, 
amounts of naevi and genetic factors are further important factors for developing MM [5]. 
Although it is widely accepted that moles on the skin can transform into MM, only 25 % of all 
MM are formed by pre-exiting naevi. Interestingly, men and women show a gender-specific 
pattern in developing MM. Men show a higher risk in developing MM and they mainly tend to 
get MM on the back, whereas woman mostly develop MM in areas close to joints [9]. Besides 
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the gender-dependent differences, MM is also an area-dependent phenomenon. It occurs 
more frequently in Northern Europe and North America as compared to Asia, Africa, and 
Latin America [3]. 
1.1.1 Treatment of MM 
In recent years, the treating opportunities for MM become much more versatile and 
successful. The approval of immune-checkpoint inhibitors, especially ipilimumab in 2011, 
nivolumumab and pembrolizumab in 2014 achieved unprecedented success in treating 
melanoma patients [2, 4]. 
Ipilimumab is an antibody towards cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on 
T cells. CTLA-4 is an immune-checkpoint molecule, which binds to B-7 proteins mainly on 
dendritic cells [10]. The activation of CTLA-4 inhibits T cells by reducing their proliferation 
and cytokine production. The use of ipilimumab prevents the exhaustion of T cells and 
restores their pro-inflammatory phenotype, as well their clonal expansion and infiltration [11]. 
Administration of ipilimumab in clinical trials increased the overall-survival by 10.1 months. A 
further phase-III study showed that combinational therapy with the conventional 
chemotherapeutic drug dacarbazine prolonged overall survival up to 11.2 months, whereas 
the dacarbazine monotherapy increased it to 9.1 months [12].   
Nivolumumab and pembrolizumab are blocking antibodies against programmed cell death 
protein I (PD-1) [13]. Similar to CTLA-4, PD-1 is an inhibitory checkpoint molecule on 
activated T cells.  Binding to its ligand PD-ligand 1 (PD-L1) or PD-ligand 2 (PD-L2) leads to 
the inactivation of effector T cells. Both PD-1 antibodies replaced ipilimumab as the first-line 
treatment [13]. Nivolumumab showed in clinical trials superior benefits compared to 
ipilimumab. Monotherapy of nivolumumab achieved a progression-free survival (PFS) of 6.9 
months and in combination with ipilimumab a median PFS of 11.5 months [14]. Nivolumumab 
monotherapy showed an overall response rate of 40 % compared to 13.9 % by dacarbazine 
treatment [15].  
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The second anti-PD-1 antibody pembrolizumab achieved in clinical trials a median PFS of 
more than 24 months and the overall response rate was about 33 %, whereas ipilimumab 
showed a response rate of 12 % in this study [16].  
Combinatorial studies of ipilimumab and nivolumumab showed a response rate of 58 %. The 
PFS increased up to 11.5 months by using both monoclonal antibodies versus 6.9 months by 
nivolumumab monotherapy. Since May 2016, the combinatorial treatment was approved as 
the most efficient therapy for MM in Germany [17].  
Targeting PD-L1 is also a promising method to treat MM patients. Clinical trials with PD-L1 
blocking antibodies like durvalumab, atezolizumab and avelumumab are ongoing. 
Besides immune-checkpoint Inhibitors, also targeted therapy improved the treatment of MM. 
About 60 % of all MM patients harbor the B-RAFV600E mutation [5]. In the recent years, 
vemurafenib and dabrafenib were approved as selective mutant B-RAF-inhibitors. Clinical 
studies reported an overall response rate of 50 % of B-RAF inhibitors in advanced 
unresectable melanoma, and the median PFS ranged from 5.3 – 7.3 months [18]. However, 
the long-term treatment is limited due to the fast acquisition of resistance mechanisms to 
those drugs [6]. One possibility to bypass the acquired resistance is to target downstream 
signaling enzymes of B-RAF. Hereby, targeting MEK is an efficient way. Trametinib and 
cobimetinib are approved MEK-inhibitors for treating MM [19]. Combined therapies with 
BRAF –and MEK-inhibitors showed improved clinical responses compared to monotherapy. 
Overall response-rates of 67 % were achieved with a median PFS of 12.3 months [20].  
In 2015, the FDA approved talimogen laherparepvec (T-VEC), a genetically modified herpes 
simplex virus, to treat MM [21]. This oncolytical virus infects normal and melanoma cells but 
replicates only in melanoma cells that result in their lysis. Furthermore, during virus 
replication, melanoma cells are forced to produce and secrete granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which stimulates the host immune system [22].  In 
clinical trials, T-VEC showed an overall response rate of 28 %, and median PFS was 
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increased to 19.6 months. T-VEC was described to be a very safe treatment with minor 
adverse effects [21, 23].   
Therefore, the unprecedented success of immunotherapy highlighted the crucial role of our 
immune system in controlling tumor development. Understanding the tumor 
microenvironment (TME) and its interaction with the immune system will help to create new 
effective treatment strategies.  
1.2  Role of the immune system in cancer 
The unprecedented success of immunotherapy demonstrated undoubtedly the importance of 
the immune system in cancer development. This led to the addition of inflammation to the 
hallmarks of cancer [24-26]. However, the idea that our immune system controls the tumor 
growth was set already in 1909. Paul Ehrlich reported that the immune system developed 
mechanisms to suppress tumor formation [27]. Later on, Mac Farlane Burnet and Lewis 
Thomas postulated in 1957: “In large long lived animals....inheritable genetic changes must 
be common in somatic cells and a proportion of these changes will represent steps toward 
malignancy. It is an evolutionary necessity that there should be some mechanism for 
elimination or inactivity of such potentially dangerous mutant cells and it is postulated that 
this mechanism is of immunological character" [28]. This hypothesis was the start of the 
immunosurveillance concept. However, the lack of experimental designs and technologies 
made it impossible to prove the concept. In 1990, new mouse models, genetic engineering 
and monoclonal antibodies provided the opportunity to prove the immunosurveillance 
hypothesis [29]. Robert Schreiber and colleagues proposed a revised version of the 
immunosurveillance concept, which was termed immunoediting and comprises of three 
different phases: elimination, equilibrium and escape [29] 
 
 
Introduction 
5 
 
1.2.1  Elimination 
Immune cells are able to recognize the malignant transformation of tumor cells. This is due to 
inflammatory signals, which are caused by tumor cells when they proliferate and damage the 
nascent tissue. Innate immune cells, like natural killer (NK) cells, dendritic cells (DC) and 
macrophages are recruited and clear the tumor cells [30]. The inflammatory environment is 
strengthened by the aberrant death of tumor cells that in turn further activate innate and 
adaptive immune cells. If in this phase, the tumors will be fully eliminated, the immunoediting 
concept ends at this point [31, 32]. 
1.2.2  Equilibrium 
The equilibrium phase is following the elimination phase when the immune cells fail to clear 
the tumor cells. The tumor is not dormant, as believed before, but rather continues to 
proliferate [33]. Hereby, the tumor cells acquire mutations due to the genetic instability of 
malignant cells. Because of the immunological pressure during this phase, a selection will 
favor tumor cells, which are less antigenic [29].  
1.2.3  Escape 
Tumor cells acquired enough properties in the equilibrium phase to avoid the immune system 
[33]. The loss of immune recognition could be achieved by three main reasons: I) Loss or 
down regulation of the major histocompatibility complex (MHC) on tumor cells. II) Impaired 
ability of antigen processing. III) lacking of antigens recognized by immune cells [34]. 
Furthermore, the tumor cells established in the equilibrium phase an immunosuppressive 
microenvironment. Hereby, different stroma and immune cells helps the tumor growing. 
Many factors were found in an immunosuppressive microenvironment that promote tumor 
growth [35, 36]. However, one major factor that protect tumor cells from the anti-tumorigenic 
immune cells are myeloid-derived suppressor cells [37].  
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Figure 1: The concept of Immunoediting. Tumor cells and immune cells are in constant interaction 
that is divided in three phases. In the “Elimination” phase, immune cells attack and kill the tumor cells. 
A high immunological pressure on tumor cells characterizes the “Equilibrium” phase. However, in this 
phase some tumor cells survive due to favoring mutations. In the “Escape” phase, tumor cells acquired 
properties that hide them from our immune system. Figure was adopted from Kalbasi et al., 2013 [38] 
 
1.3 Myeloid-derived suppressor cells (MDSC) 
MDSC represent a heterogeneous population of cells that show an immature and 
immunosuppressive phenotype [37, 39]. During the last decades, it was proven that MDSC 
play a major role in inducing an immunosuppressive TME and promote tumor progression 
[40]. Their frequency and activity was negatively correlated with tumor progression, 
metastasis, recurrence and resistance to therapy [41-43]. Especially, the response to 
immunotherapy seems to be dependent on MDSC frequency and function [44, 45]. Because 
of these aforementioned data, MDSC are considered to be a target for future therapies [46]. 
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1.3.1  Biology and function of MDSC 
MDSC are generated within the bone marrow (BM) by the alternative activation of immature 
myeloid cells (IMC) [39, 47]. Usually, IMC differentiate into mature macrophages, DC or 
granulocytes under steady-state conditions. During acute infections IMC rapidly differentiate 
into monocytes or neutrophils, which form the first line of defense against invading 
pathogens [37]. This differentiation is promoted by a short-term production of several soluble 
factors like granulocyte macrophage colony-stimulating factor (GM-CSF), tumor necrosis 
factor (TNF)-α, and interleukin (IL)-1and IL-6 [46, 47]. However, during chronic infections, 
obesity or cancer, this differentiation is altered due to a persistent secretion of those soluble 
factors. The fully differentiation of IMC is blocked, and they acquire an immunosuppressive 
phenotype, which results in the generation of MDSC [37]. They migrate to peripheral lymph 
nodes and to the site of tumor by following distinct gradients of chemokine (C-C motif) 
ligands (CCL) and C-X-C motif chemokine (CXCL) that are secreted by the TME [48, 49].  
Within the TME, MDSC inhibit effector T cells [37]. Furthermore, MDSC promote tumor 
progression by non-immunological ways. For example, they produce large amounts of matrix 
metalloproteinases (MMP), especially MMP9 [50]. Those MMP hydrolyze the extracellular 
matrix and basal membrane. This remodeling process enables tumor cells to leave the TME, 
enter into the blood stream and form metastasis [51]. It is known that tumor cells prepare the 
pre-metastatic niche before entering into the blood stream [52]. This process is still poorly 
understood but first studies indicate that MDSC play a major role in this process [53]. 
Moreover, MDSC produce large amounts of vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF) [46], key factors to induce angiogenesis. The latter is a 
further hallmark of tumor progression, as it enables nutrition, vasculature and dissemination 
of the tumor [25].       
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Figure 2: Biology of MDSC. MDSC arise from IMC in the bone marrow due to constant but weak 
activation by cytokines. MDSC leave the BM and migrate to the TME following the CCL and CXCL 
gradient released by tumor and immune cells. Within the TME, MDSC support tumor growth especially 
by suppressing T cells. Here fore, they use various mechanisms. Figure was adopted from Fleming et 
al., 2018 [46] 
1.3.2  Immunosuppressive activity of MDSC 
As mentioned before, the hallmark of MDSC biology is their capability to inhibit the function 
of effector T cells and consequently turning off the major player of anti-tumor immunity. 
Thereby, MDSC use various different inhibitory mechanisms. One mechanism is the 
production of arginase-I (Arg-1) [54], an intracellular enzyme, which is crucial for the urea 
cycle. It converts L-arginine into L-ornithine and urea. The catabolism of arginine leads to its 
depletion. Although T cells are dependent on arginine for their metabolism, they cannot 
produce arginine by themselves [55]. Therefore, the lack of arginine results in the 
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translational blockade in effector T cells, resulting in cell cycle arrest G0-G1 [56]. Furthermore, 
T cells becomes insensitive for T cell receptor (TCR) signaling because the expression of 
-chain, which is essential for the signaling,  is decreasing upon translational blockade [57].  
Next to Arg-1, MDSC produce inducible nitric oxide synthase (iNOS), which catabolize L-
arginine as well [58]. The product of the iNOS reaction is nitric oxide (NO), which can modify 
the T cell receptor by nitrosylation, resulting in less affine T cell receptors [46]. Moreover, NO 
nitrosylate important pathway mediators of the IL-2 pathway that is crucial for T cell function 
and proliferation [54, 58].  
Besides depleting L-arginine, MDSC also catabolize L-tryptophan, a further essential amino 
acid for effector T cells [59]. By the expression of indoleamine 2,3-dioxygenase (IDO), MDSC 
convert L-tryptophan into kynurenine and 3-hydroxykynurenine [46]. This catabolic 
conversion has several negative effects on T cells. First, the starvation of L-tryptophan 
results in the differentiation of CD4+ T cells into immunosuppressive regulatory T cells. 
Second, kynurenine and 3-hydroxykynurenine directly suppress effector T cells by impairing 
their function and proliferation. Third, kynurenine induces apoptosis in thymocytes [60, 61]. In 
addition, studies reported that kynurenine inhibit the anti-tumorigenic function of NK cells 
[60].  
Reactive oxygen species (ROS) is another important immunosuppressive mediator utilized 
by MDSC [37, 62]. High concentrations of ROS initiate the apoptosis of T cells. Similar to 
Arg-1, ROS can also dampen the expression of the TCR -chain. ROS interacts with NO that 
results in peroxynitrite production [41]. Like NO, peroxynitrite nitrosylate the TCR, which 
results in impaired antigen recognition and T cell signaling [46].  
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1.4  Programmed death-1 receptor/Programmed death-ligand 1  
MDSC also express high levels of PD-L1 [37]. The PD-1/PD-L1 axis becomes incredibly 
important during the last years due to the approval of anti-PD1 blocking antibodies for 
treating several cancer types [13, 63]. Originally, PD-1 was first described in 1992 when 
scientists studied novel receptors in T cells that undergo apoptosis [63]. PD-1 is up regulated 
upon activation of effector T cells and consists of a single extracellular immunoglobulin-like 
variable domain. It contains an immunoreceptor tyrosine based inhibitory motif (ITIM) and 
immunoreceptor tyrosine based switch motif (ITSM) [64]. PD-L1 and PD-L2 were discovered 
9 years later as ligands for PD-1 [63]. Both ligands consist of extracellular IgV and IgC 
domains and lack an intracellular signaling domain [64]. PD-L1, but not PD-L2, can also bind 
to CD80 (B7.1). PD-L1 and PD-L2 are widely expressed on hematopoietic cells, epithelial 
cells and endothelial cells [13].  
1.4.1  PD-1 signaling cascade in T cells 
The binding of PD-L1 to PD-1 results in inhibitory signals in T cells [65]. Upon ligation, the 
ITIM and ITSM motifs on the intracellular domain of PD-1 becomes phosphorylated. Src 
homology region 2 domain-containing phosphatase (SHP)-1 and SHP2 are recruited to the 
phosphorylated cytoplasmic tail of the PD-1 receptor [65]. The activation of SHP-1 and 
SHP-2 impairs T cell receptor signaling as SHP-1 and SHP-2 dephosphorylates important 
downstream adaptor molecules including -chain-associated protein kinase 70 (ZAP70) and 
CD3 -chain. Inhibiting these pathways leads to decreased production of interferon (IFN)- 
and IL-2, which are important cytokines to sustain effector T cell activity [65]. Moreover, 
SHP-1 and SHP-2 were shown to inhibit the PI3K/AKT pathway. Impaired AKT activity in 
CD4 T cells generates regulatory T cells [65]. 
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1.4.2  Regulation of PD-L1 expression 
Inflammatory signals were shown to be strong inducers of PD-L1 [66]. IFN- produced by 
activated T cells was described to be one of the strongest regulators [67]. Interestingly, the 
IFN- induced PD-L1 expression seems to be context dependent. IFN- neutralizing 
antibodies were shown to inhibit PD-L1 expression on tumor cells in a sarcoma mouse 
model, whereas PD-L1 expression on immunosuppressive macrophages was unchanged 
[68]. Besides IFN-, also type-I interferons induce PD-L1 expression on tumor and myeloid 
cells [69].  
Ligands for toll-like receptors (TLR) were verified to induce PD-L1 upregulation on melanoma 
cells, endothelial cells and dendritic cells [69]. Especially, ligands for TLR3, TLR4 and 
TLR7/8 were described to induce PD-L1 expression [69, 70]. Furthermore, IL-17 and 
TNF-were shown to stimulate PD-L1 expression on monocytes and prostate cancer cells 
[69]. For DC, IL-1, IL-6, IL-10 and IL-27 were demonstrated to up regulate PD-L1 [69]. In 
addition to inflammatory cytokines, also oncogenic signaling was proved to be a major driver 
for PD-L1 upregulation [66, 71]. MYC oncogene overexpression was associated with high 
levels of tumorigenic PD-L1. Targeting MYC resulted in decreased levels of PD-L1 on tumor 
cells [72]. Most tumor cells show a hyper-activated MEK-ERK signaling mainly due to 
mutated tyrosine kinases like B-RAF. Activated MER-ERK pathway was confirmed to induce 
PD-L1 upregulation on many cancer cell lines, which was abrogated upon MEK inhibition 
[66]. Activation of epidermal growth factor receptor (EGFR) and downstream effector 
molecules were proved to induce PD-L1 expression in multiple tumor models. A further 
hallmark of tumor progression is a hypoxic microenvironment. Hypoxia induces the 
transcription factor hypoxia-inducible factor (HIF)-1 that directly binds hypoxia response 
element (HRE) on the PD-L1 promoter and initiates the synthesis of PD-L1 on tumor and 
myeloid cells [73]. Recently, many micro RNA (miRNA) were associated with the regulation 
of PD-L1 [74]. Especially, miRNA-513 and miRNA-155 were shown to be important 
suppressors of PD-L1 expression at the post-transcriptional level [74].  
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1.5  Extracellular Vesicles  
Cells use various mechanisms to communicate. Besides direct cell to cell interaction and 
secretion of soluble factors, extracellular vesicles (EV) are important mediators of long range 
communication [75].  
EV consist of three subsets, which differ in their size distribution and their biogenesis [76]. 
The apoptotic bodies are 1 to 5 µm in size and are formed by cells undergoing apoptosis. To 
the second type of EV belong microvesicles (sometimes also called as ectosomes or 
microparticles). They are 100 nm – 1000 nm and are produced by the outward budding of the 
limiting plasma membrane. Exosomes form the smallest type of EV. They are described to 
be 30 nm – 150 nm in diameter and are generated within multivesicular bodies (MVB) by 
inward budding of the limiting membrane. By fusion of the multivesicular bodies with the 
plasma membrane, exosomes are released into the extracellular space and can act as a 
mediator of communication. As exosomes and microvesicles overlap in size, and most used 
isolation methods do not specifically isolate a distinct type of EV, it is recommended to use 
the general term EV [75].  
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Figure 3: Subsets of EV. EV consists of three different subsets. The smallest subsets are the 
exosomes, which are generated within MVB. By the fusion of the MVB with the plasma membrane, 
exosomes gets released into the extracellular space. The second subsets are the microvesicles. The 
outward budding of the plasma membrane creates them. The biggest subset is called apoptotic 
bodies. They are produced by cells undergoing apoptosis. Figure was adopted from György et al., 
2011 [77]. 
1.5.1  EV in cancer progression 
During the last decades, the interest on EV in cancer research gained an enormous level. 
This was especially due to the following findings: I) EV carry functional miRNA and 
oncogenes to recipient cells [78], II) EV derived from immune cells were able to present 
antigens on MHC molecules and induced T cell activation [79], and III) EV were shown to be 
crucial for organotropic metastasis formation [80].  
Since then, the understanding of the role of EV in cancer progression immensely increased. 
It was revealed that EV encourage tumor progression by promoting angiogenesis. Studies 
reported that EV-derived miRNA-17-92 regulates integrin-5, which stimulates tube 
formation and proliferation of endothelial cells [81]. Furthermore, miRNA-9 in EV was found 
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to be internalized by endothelial cells and to exhibit pro-angiogenic properties by the 
activation of JAK-STAT signaling [82]. In addition, tumor-derived EV contain high amounts of 
pro-angiogenic molecules such as VEGF, IL-8, PDGF and FGF, which augment 
angiogenesis by recipient endothelial cells. EV support directly the proliferation of tumor 
cells. Tumor-derived EV contain high amounts of miRNA-222 [83]. In an autocrine manner, 
tumor cells take up miRNA-222 containing EV that directly results in enhanced PI3K/AKT 
activity and therefore higher proliferation of tumors cells [84]. Distinct tumor-derived EV were 
reported to transport CD97 [85]. Recipient tumor cells incorporated functionally CD97 on 
their surface, which leads to enhanced activity of MAPK-signaling pathway and results in 
tumor cell proliferation. Mutated forms of epidermal growth factor receptor variant III 
(EGFRVIII) were found on the surface of EV [86]. The uptake and integration of this mutant 
EGFRVIII resulted as well in higher proliferation rates of tumor cells due to the promotion of 
anti-apoptotic pathways [87]. It was found that EV promote the formation of metastasis in 
multiply ways. Tumor-derived EV are found to express high amounts of MMP on their 
surface. These MMP remodel the extracellular-matrix and create a leaky environment that 
favors the spread of cancer cells [88]. Moreover, studies reported the potential of EV to 
promote epithelial to mesenchymal transition (EMT) [89]. 
1.6  Pathogen Recognition Receptors (PRR) 
The innate immune system evolved mechanisms to recognize invading pathogens and 
damaged cells using pathogen recognition receptors (PRR) that recognize pathogen-
associated molecular patterns (PAMP) or damage-associated molecular patterns (DAMP) 
[90]. During last decades, many families of PRR were discovered and studied. In addition to 
immune cells also epithelial and endothelial cells express PRR on their cell surface or with in 
the cytosol [90]. By recognizing the respective PAMP or DAMP, cells starts to induce their 
defense mechanisms to counteract the pathogens. They produce a distinct set of cytokines 
to upregulate their antigen-presenting activity of immune cells and to block the proliferation 
and metabolism of intracellular pathogens [91].  
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PRR are classified into four major groups: Toll-like Receptors (TLR), c-type lectine receptors 
(CLR), nucleotide-binding oligomerization domain (NOD)-like receptors and retinoic-acid-
inducible gene I (RIG-I)-like receptors (RLR) [92, 93]. 
CLR are membrane bound receptors, which are internalized upon PAMP binding. They 
mainly recognize carbohydrate structures expressed on pathogens. Two types of CLR are 
described based on the structure of recognized carbohydrates. DEC205 and macrophage-
mannose receptor belongs to the type-I CLR, whereas DCIR, DC-sign and Dectin-I are 
members of the type-II family [94]. 
Only few members of the RLR are found by now. They are expressed exclusively in the 
cytoplasm and recognize viral DNA, resulting in the production of high amounts of type-I IFN 
and, in some cases, in the initiation of apoptosis [95].  
Nod-like receptors are also intracellular sensors. They recognize peptidoglycans especially 
on intracellular bacteria. The recognition of PAMP induces the activation of the nuclear factor 
'-light-chain-enhancer' of activated B-cells (NF-B) pathway, leading to the induction of 
immune responses [96]. Furthermore, the cells undergo apoptosis [97].    
1.6.1  Diversity of Toll-like Receptors (TLR) 
In 1995, Christiane Nüsslein-Volhard and Eric Wieschaus were honored with the Nobel Prize 
for the discovery of the toll gene in Drosophila melanogaster in 1985.  Mutants of the toll 
gene in Drosophila were shown to be sensitive to fungal infections and showed impaired 
immunity. Later on, TLR were also found in mammalians and their role in innate immunity 
was intensively studied [91]. TLR are type-I transmembrane proteins, belonging to the IL-1 
receptor (IL-1R) superfamily due to their structural homology in the cytoplasmic region (TIR 
domain) [98]. However, the extracellular domain of IL-1R contains three conserved 
immunoglobulin-like motifs, whereas the extracellular domain of TLR consists of leucine-rich 
repeats that are important in the recognition of PAMP and DAMP [98]. 13 different TLR were 
described so far [91]. TLR1, TLR2, TLR4, TLR6 and TLR10 are membrane-bound receptors 
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on the plasma membrane and TLR3, TLR7, TLR8 and TLR9 are expressed intracellularly on 
the endosomal membrane. TLR11, TLR12 and TLR 13 were only identified in mice [91].  
1.6.2  TLR ligands 
TLR recognize a broad spectrum of different PAMP. Lipoproteins and peptidoglycans from 
different gram-positive bacteria are recognized by TLR1, TLR2 and TLR6. TLR4 recognizes 
lipopolysaccharides (LPS) on the surface of gram-negative bacteria. Flagelin, a major protein 
of the bacterial Flagella, is recognized by TLR5. TLR7 and TLR8 sense intracellular single-
stranded viral RNA, whereas TLR9 recognize bacterial and viral DNA upon CpG motifs [91, 
99]. Ligands of TLR10 are still under discussion [100]. TLR11 and TLR12 which are only 
found in mice recognize profiling, a component of the protozoa Toxoplasma gondii. TLR13 
were described to differentiate between bacterial and host ribosomes due to sequence-
specific motifs [99]. Recently, more non-pathogenic TLR ligands were found. In particular, 
ligands that are associated with damaged cells like oxidized lipoproteins, HMGB1 and S100 
proteins were described to induce TLR signaling [101-104]. Table 1 shows an overview of all 
TLR with their respective ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
17 
 
 
Toll-like receptor Ligand Source 
TLR1 triacyl lipopeptides Gram positive/ negative bacteria 
TLR2 Glycolipids 
Lipopeptides 
Lipoproteins 
lipoteichoic acid 
HSP70 
zymosan  
Gram positive/ negative bacteria 
Gram positive/ negative bacteria 
Gram positive/ negative bacteria 
Gram positive bacteria 
Host 
Fungi 
TLR3 double-stranded RNA viruses 
TLR4 LPS 
Several HSP 
Fibrinogen 
Heparan sulfate 
Hyaluronic acid 
nickel 
Gram negative bacteria 
Host 
Host 
Host 
Host 
Surfaces 
TLR5 Flagellin 
Profilin 
Gram positive/ negative bacteria 
Toxoplasma gondii 
TLR6 diacyl lipopeptides Mycoplasma 
TLR7 single-stranded RNA RNA viruses 
TLR8 single-stranded Viral RNA 
bacterial RNA 
RNA viruses 
Gram positive/ negative bacteria 
TLR9 unmethylated CpG DNA Gram positive/ negative bacteria & 
viruses 
TLR10  triacylated lipopeptides Gram positive/ negative bacteria 
TLR11 (mouse) Profilin Toxoplasma gondii 
TLR12 (mouse) Profilin Toxoplasma gondii 
TLR13 (mouse) bacterial ribosomal RNA 
sequence "CGGAAAGACC" 
Gram positive/ negative bacteria 
Viruses 
 
Table 1: TLR ligands and their source. Modified from Wikipedia.org 
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1.6.3  TLR signaling 
The activation of TLR signaling induces inflammatory cytokine production, leading to the 
stimulation of adaptive immune responses [91]. Binding of the respective ligand to 
the TLR activates the TIR domain, which was found in many IL-1R and TLR 
molecules. It contains three boxes, which are important for protein-protein interaction 
(box1 and box2) and cellular localization (box3) [105]. The TIR domain of TLR can 
bind five distinct adaptor molecules. Myeloid differentiation primary response 88 
(MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF) are the 
best studied for TLR signaling [98, 99]. MyD88 binds to all TLR except TLR3, 
whereas TRIF is found on TLR4 and TLR3 [91]. Depending on the recruited adaptor 
molecule, various kinases, especially IL-1R associated kinase (IRAK) 4 or ubiquitin 
ligases (especially TNF receptor associated factor (TRAF) 6 becomes activated. 
IRAK4 and TRAF6 phosphorylate further downstream molecules/kinases that 
activate further proteins dependent on the adaptor molecule that was recruited to the 
TLR [91, 98, 99]. The TLR signaling results in the activation of NF-B that induces 
the production of various inflammatory cytokines and chemokines. Furthermore, the 
TLR signaling induces the activation of p38 MAP kinase (MAPK) and JNK MAPK 
pathways [105]. Type-I IFN will be also produced due to the activation of interferon 
response factor (IRF) 3 and 7 [91, 99].  
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Figure 4: Signaling pathway in TLR. TLR recognizes specific PAMP and DAMP from pathogens or 
Host cell. TLR3, TLR7, TLR8 and TLR9 are found on endosomal/lysosomal membrane, whereas the 
others are localized on the plasma membrane. Upon binding to its respective ligand, TLR recruit 
adaptor protein MyD88 or TRIF. MyD88 recruits IRAK4. Through the interaction of IRAK4 and TLR, 
IRAK1 becomes phosphorylated and binds TRAF6. TRAF6 activates NF-B through phosphorylation 
of its inhibitor. Furthermore, TRAF6 activates MAPK signaling that result in activated JNK and p38 
pathways. These transcription factors foster the transcription of inflammatory genes and cytokines. In 
addition, adaptor molecule TRIF recruits RIP1, which in turn activates TRAF3 that promotes the 
recruiting of IB kinase (IKK) / Tank-binding kinase 1 (TBK1), leading to the phosphorylation of IRF3. 
IRF transmigrate to the nucleus and activates Type-I IFN and IFN-induced genes [106].  
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1.7  Heat-shock proteins 
Cells developed mechanisms to counteract stress conditions. Hereby, they evolved a class 
of highly conserved proteins that are called chaperons. They sense damaged or miss-folded 
proteins. and refold them or mark for lysosomal degradation [107].  
Heat-shock proteins (HSP) belong to the biggest class of chaperones. They were discovered 
in 1962 in Drosophila melanogaster, as a family of genes that are induced upon heat-shock 
and refold heat-damaged proteins [108].  HSP have multiple acting as a molecular 
chaperone and being involved in many cellular responses, development and differentiation 
[109].  
In mice and humans, five classes of HSP were defined. They are classified based on their 
molecular mass and sequence homology: Hsp27, Hsp60, Hsp70, Hsp90, and Hsp110 [110]. 
Each HSP family has members that are expressed constitutively and those that are induced 
under stress conditions. Every singly HSP has its own specific role and are expressed in 
specific organelles. Furthermore, due to their specific binding groove, they have a distinct 
and specific group of proteins that they bind and modulate[109].  
1.7.1  Hsp90 family 
Members of the Hsp90 family are one of the most abundant proteins in the cell [111, 112]. 
They account for 1 – 2 % of all cellular proteins. Hsp90 members are found in the 
endoplasmatic reticulum, mitochondria and cytosol. Two main members are expressed in the 
cytoplasma: constitutively expressed Hsp84 (Hsp90β) Hsp86 (Hsp90 induced upon 
stressed conditions like oxidative stress or heat-shock [112] 
Under steady-state, Hsp90 regulates the maturation of proteins, intracellular trafficking, 
lysosomal degradation and signaling pathways [111]. In stressed cells, Hsp90 is mainly 
responsible for preventing aggregation of proteins and refolding damaged proteins [113]. For 
their chaperone activity, Hsp90 homodimers use ATP to undergo conformational changes.  
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For most of the proteins, Hsp90 needs the support of Hsp70 and Hsp40, which act 
downstream of Hsp90. Compared to Hsp70 and other HSP, Hsp90 is more specific to 
targets. The Hsp90 chaperone complex activity is described in detail in figure 5 [111] [109].  
HSP90 is considered as a major driver of cancer progression [114, 115]. Cancer cells utilize 
the activity of HSP90 that interacts with many oncogenes, like B-Raf, mutated p53, c-MET 
and prevents their degradation. Furthermore, cancer cells produce enormous amounts of 
proteins. To survive this proteotoxic stress, cancer cells are dependent on the proper 
function of HSP90 [109].  
Recent studies showed a beneficial effect of targeting the HSP90 family proteins. The main 
anti-HSP90 drug used in clinical trials is 17-DMAG, the natural occurring geldanamycin found 
in Streptomyces hygrocopicus [116]. It mainly binds competitively to the ATP-binding side 
and inhibits the chaperone activity of HSP90. Pre-clinical trials with 17-DMAG showed 
antiangiogenic and antitumor activity in mouse melanoma models. In human epidermal 
growth factor receptor 2 (Her-2) -positive breast cancer, 17-DMAG also showed beneficial 
effects [117]. Her-2 interacts with HSP90. Due to the lack of HSP90 activity, Her-2 showed 
higher degradation. Besides anti-tumor effects, 17-DMAG was described to inhibit 
inflammation, mainly by blocking the NF-B pathway. There are many phase I and II clinical 
trials ongoing in different cancer entities with 17-DMAG used alone or in combination with 
other agents [116].  
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Figure 5: The Hsp90 chaperone complex. Freshly translated peptides are linked to the 
HSP70/HSP40 complex by hydrophobic residues. The Hsp70/Hsp40 complex carries the client to 
HSP90 dimers. HOP supports the binding of Hsp70/Hsp40 to Hsp90. HOP also facilitates the transfer 
of the client to Hsp90. Exchange of ADP to ATP leads to the dissociation of the Hsp70/Hsp40 complex 
and close the Hsp90 complex with the client. P23 stabilize the complex. Upon ATP hydrolysis p23 and 
the client dissociates from the Hsp90 complex as fully maturated and folded protein[109]. 
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2 Aim of the project 
The aim of this study was to investigate the role of tumor-derived EV in the induction of 
immunosuppression in malignant melanoma. Here, we focused on the interaction between 
cells from a myeloid origin and melanoma-derived EV. In particular, we studied the effect of 
EV isolated from the Ret melanoma cell line on immature myeloid cells (IMC) from the bone 
marrow of C57BL/6 mice. In order to test if Ret-EV are able to convert IMC into 
immunosuppressive MDSC, we analyzed immunosuppressive mediators upon Ret-EV 
treatment and performed T cell proliferation studies to evaluate the immunosuppressive 
potential. Furthermore, we investigated the signaling pathways involved in the 
reprogramming of IMC into MDSC and search for key targets inducing those signaling 
pathways. Finally, we performed tumor growth studies with Ret cells deficient in essential 
genes for the reprogramming of IMC into MDSC to test if we can block the EV-mediated 
induction of immunosuppression in malignant melanoma.  
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3  Material and Methods 
 
3.1  Materials 
3.1.1  Mouse strains 
Wild type C57BL/6 mice were purchased from Charles River laboratories (Sulzfeld, 
Germany). Those mice were crossed and kept under pathogen-free conditions in the animal 
facility of the German Cancer Research Center (Heidelberg, Germany). Tlr2-/- and Tlr7-/- mice 
with C57BL/6 background were obtained from Beatrix Schumak, University of Bonn. Tlr4-/-; 
MyD88-/- and MyD88-/-/Trif-/- mice with C57BL/6 background were obtained from Carsten 
Kirschning, University of Essen-Duisburg. Experiments were performed in accordance with 
government and institutional guidelines and regulations. 
3.1.2  Cell lines 
The Ret cell line (Ret) was isolated from cutaneous melanoma developed in Ret transgenic 
mice [118] and cultured in RPMI-1640 supplemented with 10 % FBS and 1% Penicillin-
Streptomycin [119].  
MSC-1 and MSC-2 cells were established by isolating splenic cells from BALB/c mice 
followed by virus-induced immortalization [120]. They reflect a cell line to study myeloid 
suppressive cells. MSC-1 cells are permanently suppressive, whereas MSC-2 are 
suppressive upon treatment with IL-4. (MSC-1 and MSC-2 cells were kindly provided by Dr. 
Stefano Ugel, University of Verona) 
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3.1.3  Laboratory equipment 
Device  Name Provider  
Balance BP 3100P Sartorius 
Cell culture incubator Hera cell  Heraeus  
Centrifuges  BiofugeprimoR  
MEGAFUGE 40R  
Labofuge 400R  
Heraeus  
Heraeus 
Heraeus   
Confocal microscope TCS SP2 Leica 
Flow cytometer FACS Canto II BD Biosciences  
Flow cytometer  FACS Lyric BD Biosciences  
Heating block  Digital Block Heater HX-2  Peqlab  
Imaging system  Fusion SL  VilberLourmat  
Laminar flow hood Hera safe Thermo Electron Cooperation 
Magnetic stirrer RCT basic IKA Werke 
Microplate Reader Tecan infinite M200 Tecan 
Microscope DMIL Leica 
N2 tank   
Nanoparticle tracking system NanoSight NS300 NanoSight 
Pipettes  Transferpette ® S  Brand  
Power supply  PowerPacTM HC High Current  BioRad  
Real-Time PCR machine MX3005 qPCR Systrm  Stratagene  
Shaker  Logic shaker  NeoLab  
Thermal Cycler  DNA Engine Peltier Thermal Cycler  Biorad  
Transfer device  iBlotTM Gel Transfer Device  Thermo Scientific  
Ultracentrifugation rotor Surespin 630 Sorvall 
Ultracentrifuge  SorvallDiscovery 90SE  Hitachi  
Vortexer REAX top 
Vortex Genie 2 
Heidolph 
Scientific Industries 
Water bath DC3 HAAKE, GFL 
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3.1.4  Cell culture products 
Product Company Catalog No. 
100 μm cell strainer BD CLS431751-50EA 
12-well flat bottom with lid BD 353043 
15 mL conical tubes Falcon 352096 
24-well flat bottom with lid Greiner bio-one 622160 
40 μm cell strainer BD  
5 mL round-bottom polypropylene  tubes with cell 
strainer 
BD 352235 
5 mL round-bottom polypropylene tubes BD 352008 
50 mL conical tubes Falcon 352070 
6-well flat bottom with lid Thermo Fisher 
Scientific 
140675 
96-well flat bottom with lid TPP® 92096 
96-well U-bottom with lid Sigma Aldrich M9436-100EA 
Amicon® Ultra Centrifugal tube Merck Millipore UFC905024 
Cell culture flasks T75 Sigma Aldrich C7231-120EA 
Cryovial, 2 mL sterile Sigma Aldrich V5760-500EA 
 Filter tips: 20, 200, 1000 μL Steinbrenner L1000 
Safe lock tubes: 0.5, 1.5 and 2 mL Eppendorf SL-GPS-L10, 
L250, 
serological pipettes: 5, 10 and 25 mL, sterile Greiner bio-one 606180; 607180 
Syringe 1 mL BD  
Cellstar Cell culture flask 25 cm2  
 
Greiner  
 
658170  
 
iBlotTMGel Transfer Stacks  
 
Thermo Fisher 
Scientific  
 
IB24002  
 
Neubauer chamber  
 
Brand  
 
 
Needles Sterican®  
Ø 0.40 x 20 mm  
B. Braun  
 
4657705  
 
PVDF membrane  
 
Thermo Fisher 
Scientific  
 
88520  
 
Stericup&Steritop 0.22 μm Millipore Express PLUS 
membrane  
 
Merck Millipore  
 
SCGPU02RE  
 
TC dish, 150 Standard  
 
Sarstedt  
 
3903  
 
ThickBlot Filter Paper  
 
BioRad  
 
1703  
 
 
Material and Methods 
27 
 
3.1.5  Cell culture media 
Product Company Catalog No. 
0.4 % Trypan blue solution Sigma Aldrich T8154 
2-β-Mercaptoethanol (50 mM) Gibco 31350 
Bovin serum albumin Sigma 7030-50G 
Dimethylsulfoxid (DMSO) Merck 109678 
Dimethylsulphoxide Hybrid Max (DMSO) Sigma Aldrich 472301-100ML 
DPBS (1x) Gibco 14190-094 
Fetal Bovine Serum PAN Biotech GmbH 3702-P260718 
HEPES Buffer (1M) Sigma Aldrich H0887 
Hygromycin B Carl Roth 1287.1 
Kanamycinsulfate Sigma Aldrich 60615 
MACS BSA Stock Solution (10 %) Miltenyi Biotec 130-091-376 
MEM NEAA (100x) Gibco 11140-035 
OptiMEMTM Gibco  
 
31985070  
 
Penicillin/ Streptomycin PAA P11-010 
RPMI Medium 1640 (1x) + GlutaMAX™ Gibco 61870-010 
sodium pyruvate (100 mM) Gibco 11360-039 
UltraPure™ EDTA (0.5M, pH 8.0) Gibco 15575 
 
3.1.6  Chemicals 
Product Company Catalog No. 
10 % Tween® 20 Solution  Biorad  161-0781  
 
10 x Permeabilization Buffer  eBioscience  
 
00-8333-56 
7-AAD BD 51-68981E 
 
ACK lysis buffer  
 
Gibco  
 
A10492-01  
 
Acrylamide solution  
 
Carl Roth  
 
2267.2  
 
Albumin IgG free  
 
Carl Roth  
 
3737.4  
 
Amiloride,5’-(N,N-Dimethyl)-hydrochloride  
 
Enzo  
 
ALX-550-261-M005  
 
Ammonium-persulfate (APS)  
 
Sigma-Aldrich  
 
A-3678  
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ATX Ponceau S red staining solution  
 
Sigma-Aldrich  
 
09189-IL-F  
 
Carboxyfluorescein succinimidyl ester 
(CFSE) 
Biolegend 423801 
Clear PAGE LDS sample buffer (4x)  
 
Invitrogen  
 
MP0007  
 
Fluoromount-G Southern Biotech 
 
0100-01 
 
Glycine  
 
Carl Roth  
 
3908.1  
 
KNK-437  
 
Sigma Aldrich  
 
SML0964-5MG  
 
LB-Agar  
 
Carl Roth  
 
X965.1  
 
LB-Media  
 
Carl Roth  
 
X968.1  
 
Lipofectamine 3000 Transfection Reagent  
 
Invitrogen  
 
L3000001  
 
Methanol  
 
Carl Roth  
 
8388  
 
MISSION® shRNA Bacterial stock  
 
Sigma Aldrich  
 
SHCLNG  
 
MISSION® TRC2 pLKO.5-puro Non-
mammalian Control Plasmid DNA  
 
Sigma Aldrich  
 
SHC202  
 
PageRuler Protein ladder prestained  
 
Thermo Fisher Scientific  
 
26616  
 
Pierce® ECL Western Blotting Substrate  
 
Thermo Fisher Scientific  
 
#32106  
 
Pierce® RIPA Buffer 100 ml  
 
Sigma Aldrich  
 
89900  
 
Powdered milk  
 
Carl Roth  
 
T145.3  
 
Roti-Phenol/ Chloroform/Isoamylalkohol  
 
Carl Roth  
 
A156.1  
 
Rotiphorese Gel 30 (37,5:1)  
 
Carl Roth  
 
3029.1  
 
SDS  
 
Carl Roth  
 
0183.3  
 
SIG10 5α Chemically Competent cells  
 
Sigma Aldrich  
 
CMC  
 
Temed  
 
Biorad  
 
#1610800  
 
TRIS  
 
Carl Roth  
 
0188.3  
 
Trizol ® Reagent  
 
Life Technologies  
 
15596018  
 
Trypan Blue Solution  
 
Sigma Aldrich  
 
T8154  
 
Trypsin  
 
ThermoFisher Scientific  
 
15400054  
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3.1.7  Kits 
Product Company Catalog No. 
Arginase Activity Assay Kit Sigma Aldrich MAK112-1KT 
CD8
+ 
T cell isolation kit Miltenyi Biotec 130-104-075 
CellROX® Reagents  Thermo Fisher Scientific C10422 
FoxP3/ Transcription Factor Fixation/ 
Permeabilisation Concentrate and Diluent 
eBioscience 00-5521-00 
Isolate II Biofluids RNA Kit Bioline BIO-52086 
Mouse IFN-γ ELISA MAX™ Deluxe Biolegend 430804 
 
Myeloid-derived Suppressor cell isolation kit Miltenyi Biotec 130-094-538 
NOS Detection Kit Cell technologies NOS200-2 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific 23227 
Pierce™ LAL Chromogenic Endotoxin Quantitation 
Kit 
Thermo Fisher Scientific 88282 
SensiFAST™ SYBR® Lo-ROX Kit Bioline BIO-94020 
Toxisensor™ Chromogenic LAL Endotoxin Assay GeneScript L00350 
Venor ® GeM Classic Mycoplasma Detection Kit Minerva 11-1050 
3.1.8 Primers for mRNA 
Primer  Orientation Sequence 
18S RNA forward 
reverse 
5’-CGCGGTTCTATTTTGTTGGT-3'  
5’-AGTCGGCATCGTTTATGGTC-3'  
 
IL-1 forward 
reverse 
5’-TGTGAAATGCCACCTTTTGA-3'  
5’-GGTCAAAGGTTTGGAAGCAG-3'  
 
IL-6 forward 
reverse 
5’-TGATGCACTTGCAGAAAACA-3' 
5’-ACCAGAGGAAATTTTCAATAGGC-3' 
 
Il-10 forward 
reverse 
5’-GACGTGGAAGTGGCAGAAGAG-3'  
5’-TGCCACAAGCAGGAATGAGA-3'  
 
IL-17 forward 
reverse 
5’-CAGCAGCGATCATCCCTCAAAG-3' 
5’-TGAGGTTGACCTTCACATTCTGGA-3' 
 
TNF- forward 
reverse 
5’-GACGTGGAAGTGGCAGAAGAG-3' 
5’-TGCCACAAGCAGGAATGAGA-3' 
 
COX2 forward 
reverse 
5’-TCTGGAACATTGTGAACAACATC-3' 
5’-AAGCTCCTTATTTCCCTTCACAC 
 
PD-L1 forward 
reverse 
5’-TGGACAAACAGTGACCACCAA-3'  
5’-CCCCTCTGTCCGGGAAGT-3'  
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3.1.9  Antibodies 
Product Clone Company Catalog No. 
Alix 1A12 Santa Cruz Sc-53540 
Anti-Mouse IgG from rabbit Polyclonal Sigma-Aldrich A9044-2ML 
Anti-Rabbit IgG from Goat Polyclonal Sigma-Aldrich A0545-1ML 
anti-Tubulin Beta 3-Alexa Fluor 594 AA13 Biolegend TUBB3 
ARG-1-APC MAB58681 RnD Systems IC5856A 
Calreticulin D3E6 Cell signaling 12238S 
CD11b-APC-Cy7 M1/70 BD 557657 
CD45-V500 HI30 BD 557657 
CD81 D5O2Q Cell signaling 10037S 
CD8-eFluor 450 53-6.7 eBiosciences 48-0081-80 
CD9 EM04 Thermo Fisher Scientific MA1-10309 
FcR Blocking Reagent 2.4G2 BD 553141 
GAPDH 1D4 Biolegend 919501 
Gr-1-PE-Cy7 RB6-8C5 BD 552985 
HSP72 Polyclonal GeneTex GTX111088 
HSP86 Polyclonal Novus Biologicals NB120-2928 
Human Phospho-RelA/NF- B S536 RnD Systems MAB72261-SP 
Human/Mouse RelA/ NF- B D14E12 RnD Systems MAB50781 
PD-L1-BV421 MIH5 BD 564716 
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3.1.10  shRNA 
TRC Number Gene Clone ID Company 
TRCN0000321086 HSP90AA1 NM_010480.5-589s21c1 Sigma-Aldrich 
TRCN0000321084 HSP90AA1 NM_010480.5-2221s21c1 Sigma-Aldrich 
TRCN0000321007 HSP90AA1 NM_010480.5-1282s21c1 Sigma-Aldrich 
TRCN0000321085 HSP90AA1 NM_010480.5-440S21c1 Sigma-Aldrich 
TRCN0000321083 HSP90AA1 NM_010480.5-2743s21c1 Sigma-Aldrich 
3.1.11  Primers for miRNA 
Primer Sequence 
hsa-21-5p UAGCUUAUCAGACUGAUGUUGA 
hsa-125a-5p UCCCUGAGACCCUUUAACCUGUGA  
hsa-125b-5p UCCCUGAGACCCUAACUUGUGA  
hsa-146a-5p  UGAGAACUGAAUUCCAUGGGUU  
hsa-155-5p  UUAAUGCUAAUUGUGAUAGGGGU  
mmu-690  AAAGGCUAGGCUCACAACCAAA  
hsa-let7e-5p  UGAGGUAGGAGGUUGUAUAGUU  
U6  
 
GUGCUCGCUUCGGCAGCACAUAUACUAAAAUUGGAACGAU 
ACAGAGAAGAUUAGCAUGGCCCCUGCGCAAGGAUGACACG 
CAAAUUCGUGAAGCGUUCCAUAUUUUU 
3.1.12  Cell culture media 
Name Composition 
Freezing medium 75 % FBS 
25 % DMSO 
 
MDSC exosome-depleted medium  
 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS (Ultracentrifuged at 23000 rpm for 16h) 
1 % Penicillin/ Streptomycin 
10 mM HEPES  
1 mM Sodium Pyruvate 
50 μM β-Mercaptoethanol 
1 mM MEM Non-essential amino acids 
 
MDSC Medium  
 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS 
1 % Penicillin/ Streptomycin 
10 mM HEPES 
1 mM Sodium Pyruvate 
50 μM β-Mercaptoethanol 
1 mM MEM Non-essential amino acids 
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MSC Medium  
 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS 
1 % Penicillin/ Streptomycin 
10 mM HEPES 
 
Ret Medium  
 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS  
1 % Penicillin/ Streptomycin 
 
3.1.13  Buffers 
Name Composition 
1 x TBS  
 
5 ml 1 M Tris/HCl, pH 8 
15 ml 1 M NaCl 
470 ml ddH2O 
10 % Separating polyacrylamide gel  
 
21.3 ml ddH2O  
13.3 ml 30 % Acrylamide solution  
5.3 ml 3 M Tris/HCL, pH 8.8  
400 μl 10 % SDS  
133 μl 10 % APS  
TEMED 
10 x Running buffer 30 g Tris base  
144 g Glycine  
10 g SDS  
10 l ddH2O 
10 x Transfer buffer  
 
121.2 g Tris base 
576 g Glycine 
4 l ddH2O 
Blocking buffer for western blot 
 
DPBS 
3 % BSA 
0.05 % Tween-20 in TBS 
Blocking buffer for immunofluorescence 
 
DPBS 
5 % FBS 
0.3 % Triton X-100 
FACS buffer DPBS 
2 % FBS 
0.2 % NaN3 
MACS buffer DPBS 
1% BSA 
0.5 mM EDTA 
NP-40 lysis buffer  
 
50 mMTris HCl, pH 8.0 
150 mM NaCl 
5 mM EDTA 
10 % NP40 
1 x Protease Inhibitor 
Stacking polyacrylamide gel  
 
6 ml ddH2O 
1.35 ml 30 % Acrylamide solution 
2.5 ml 0.5 M Tris/HCl, pH 6.8 
100 μl 10 % SDS 
100 μl 10 % APS 
10 μl TEMED 
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3.1.14  Software for data analysis 
Product Version Company 
Flow Jo 7.6.1 Tree Star Inc. 
GraphPad PRISM 5 GraphPad Software Inc. 
NanoSight NTA software  3.0 0064 NanoSight 
 
 
3.2  Methods 
3.2.1  Isolation of EV 
To study the interaction between melanoma-derived EV and the immune system, we 
established a protocol for isolating EV from the murine Ret melanoma cell line (Ret).  Here, 
we used a modified EV-isolation protocol described by Lobb and Möller [121].  First, Ret cells 
were expanded in 100 x 75 cm2 cell culture dishes. When Ret cells reached a confluence of 
80-90 %, the media was discarded and Ret cells were washed with 5 ml PBS. PBS was 
discarded and serum-free Ret culture media was added to Ret cells. We chose to take 
serum-free media to exclude any exogenous vesicles that are present in the commercial 
available serum. After 24 h supernatant was taken and replaced by complete media. After 
Ret cells recovered from starvation stress, the procedure was repeated up to three times. 
The collected EV conditioned supernatant was frozen at -20 °C. On the day of isolation, the 
EV-containing supernatant was thawed at 37°C. The supernatant was sterile filtered through 
0.22 µm filters, followed by a 100 kDA size exclusion filtration at 3800 g for 30 min at RT 
using Amicon Ultra Centrifugal Filters. This allowed us to get rid of proteins smaller than 
100 kDA. After the size exclusion filtration, the concentrate was filled up with PBS and ultra-
centrifuged for 90 min at 100.000 g and 4 °C. Afterwards, the Pellet was re-suspended in 
500 µl sterile PBS and stored at -20 °C. The EV isolation method is illustrated schematically 
in Figure 6.  
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Figure 6: Isolation of Ret-EV. Ret-EV containing supernatant was sterile filtered with 0.22 µm filters. 
Afterwards, sterile supernatant was concentrated by 100 kDA size exclusion filtration. The concentrate 
was ultra-centrifuged by 100.000 g ultracentrifugation at 4°C for 90 min. EV-containing Pellet was re-
suspended in sterile PBS. 
3.2.2 Characterization of EV 
3.2.3  Nanoparticle tracking analysis 
To measure the concentration and size distribution of EV, we performed nanoparticle 
tracking analysis (NTA). This method calculates the size and concentration of EV according 
to the scattered laser light, which results due to the Brownian movement of particles. For this, 
EV were diluted 1:1000 in sterile filtered PBS and transferred via a 1 ml syringe into the 
detection chamber of the NanoSight NS300 microscope. Laser was switched on and focused 
via the NanoSight NTA software 3.0 0064. Camera level was set on seven and detection threshold 
on five. Capturing of EV was recorded for five times each 60 seconds. Temperature was 
monitored and updated after each run. After each batch of EV, detection chamber was 
washed with sterile filtered PBS. 
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3.2.4  Immunogold labeling of Ret-EV 
To visualize EV and the EV-marker CD81 on EV, electron microscopy was done. Here, 
Immunogold labeling and detection via electron microscope was performed by the DKFZ 
core facility. Briefly, EV were labelled with 1:50 diluted rabbit anti-CD81 antibody followed by 
the detection of CD81-Antibody with 10 nm protein-A-Gold (Au10). Images were taken with 
an EM910 (Carl Zeiss, Oberkochen, Germany) at 80 kV and images were registered with a 
CCD-Camera (TRS-system, Tröndle, Moorenweis, Germany) using the proprietary software 
ImageSP. 
3.2.5  MicroRNA microarray 
For the isolation of miRNA from Ret-EV, we used the ISOLATE II Biofluids RNA Kit from 
Bioline (Germany). Here, we loaded 50 µg Ret-EV onto the column and followed the 
manufactures protocol. After isolation of whole RNA, concentration was determined via 
Nanodrop device and quality check was investigated by using Bioanalyzer. MicroRNA 
microarray was kindly performed by the DKFZ genomics and proteomics core facility using 
Mouse miRNA Microarray from Agilent. 
3.2.6  Confocal microscopy  
To test weather Ret-EV are taken up by myeloid cells, we performed uptake studies using 
confocal microscopy. First, 50 µg Ret-EV or PBS as a control were stained with 5 µM CFSE 
for 5 min at 37 °C. Labeled Ret-EV and PBS were transferred into ultracentrifugation tubes 
and filled up with PBS. Ret-EV and control was then ultra-centrifuged for 90 min at 100.000 g 
and 4 °C to wash out CFSE and afterwards re-suspended in sterile PBS. MSC-1 cells that 
were seeded onto cover slips in 6-well plates before were treated with labeled Ret-EV and 
control for 24 h. Next day, supernatant was aspirated and MSC-1 cells were fixed using 2 ml 
4 % paraformaldehyde for 15 min at RT. Paraformaldehyde was removed afterwards and 
fixed MSC-1 cells were rinsed three times with PBS for 5 min each. Afterwards, MSC-1 cells 
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were blocked for 60 min at RT using blocking buffer followed by three times rinsing with PBS 
for 5 min. The blocked MSC-I cells were then stained for their cytoskeleton using 1:400 in 
blocking buffer diluted anti-Tubulin Beta 3 Antibody for 60 min at RT. After the staining, the 
cells were washed three times with PBS and mounted using Fluoromount-G overnight at RT. 
Images were taken by Diego (Medical University Mannheim) using Leica TCS SP2 confocal 
microscope. 
3.2.7  Coupling of EV on latex beads 
The size of EV are under the size threshold of the BD Canto and BD Lyric flow cytometers. 
To increase the size of EV and therefore, to allow flow cytometry analysis of EV, we had to 
couple them on latex beads. For this purpose, we diluted 1 µl of 4 µm latex beads with 
1000 µl PBS. 50 µg of EV were added to the latex beads and incubated for 60 min at RT on 
a shaking platform (900rpm). Afterwards, we added 100 μl of 1M Glycin/PBS and 100 μl of 
10 % BSA in PBS to block the latex beads. Blocking was done for 30 min at RT on a shaking 
platform. The beads were washed with 1 ml FACS buffer at 13.000 g for 2 min two times. 
After washing, 1 µl primary antibody in 100 µl FACS buffer was added to the EV-coupled 
latex beads and stained for 60 min at 4 °C in the dark. After the staining, EV-coupled latex 
beads were washed twice at 13.000 g for 2 min with 1 ml FACS buffer. Subsequently, 1 µl of 
secondary antibody in 100 µl FACS buffer was added and incubated for 60 min at 4°C in the 
dark, followed by two times washing at 13.000 g for 2 min with 1 ml FACS buffer. After 
washing EV-coupled latex beads were ready for flow cytometry.   
3.2.8  Gating of latex beads 
In order to analyze EV-coupled on latex beads, we needed an appropriate gating strategy. 
The gating strategy is shown in Figure 7. First, Forwardscatter (FSC) area (A) was set 
against Sidewardscatter (SSC) area (A) to gate on latex beads, based on their morphology. 
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Afterwards, the PE intensity was compared against the secondary PE-conjugated antibody 
as a negative control (shown in red) and CD9-PE staining (in blue) as a positive control. 
 
Figure 7: Gating strategy of EV-coupled on latex beads. 
 
3.3  Biochemical methods 
3.3.1 Protein isolation 
Cells: For the protein isolation, we used 1 x 106 cells of the respective cell line. Cells were 
transferred to an Eppendorf tube and washed with PBS at 300 g for 5 min at 4 °C. 
Afterwards, cells were re-suspended in 300 µl NP-40 lysis buffer. The cells were lysed for 
30 min at 4 °C on a shaking platform. After cell lysis, the cell debris was removed by 
centrifugation at 13.000 g for 10 min at 4 °C. The supernatant was transferred to a new 
Eppendorf tube and stored at -20 °C. If protein was needed for Western blot analysis, lysate 
was mixed with LDL-buffer supplemented with 5 % -mercaptoethanol in a ratio of one to 
four prior storage. 
EV: For the protein isolation we used 20 - 30 µg of respective EV. We add 1 x LDL-sample 
buffer supplemented with 5 % -mercaptoethanol to the EV. Then, EV were boiled at 95 °C 
for 5 min and stored at -20 °C.  
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3.3.2  Bicinchoninic-acid assay 
To determine the protein concentration of cell lysate or EV, we performed the Bicinchoninic-
acid assay (BCA) by using the Pierce™ BCA Protein Assay Kit. First, we prepared the 
working reagent by diluting 4.9 ml of BCA Reagent A with 0.1 ml of BCA Reagent B. Then, 
0.2 ml of the working reagent was transferred to wells of a 96-well microplate containing 
either 25 µl of the premixed protein standard or the unknown protein sample. The mixture 
was incubated for 30 min at 37 °C. After incubation, plate was cooled down to RT followed by 
the measuring of the absorbance at 562 nm using the microplate reader.  
3.3.3  SDS-polyacrylamide gel electrophoreses (SDS-PAGE) 
SDS-Page represents a gel electrophorese-based method to separate protein mixtures 
according to their molecular weight. For this purpose, premade SDS-gels were inserted into 
electrophoresis chambers and the device was filled up with 1 x running buffer. 10 – 20 µg of 
proteins were loaded into the wells of the SDS gel, as well 7 µl of the protein ladder. Proteins 
were separated at 80 V until the leading front runs out of the SDS gel. 
3.3.4  Western blot analysis 
After the SDS-PAGE was finished, the separated proteins on the SDS-gel were transferred 
onto a Polyvinylidenfluorid (PVDF) membrane. For this, we used the semi-dry botting 
technique. First, three Whatman papers were soaked with 1 x transfer buffer and put onto the 
anode of the blotting device. Then, the PVDF was activated in methanol and washed in 
ddH2O, followed by soaking in 1 x transfer buffer. The activated PVDF membrane was 
placed on the Whatman papers. The SDS-gel was equilibrated in 1 x transfer buffer and 
placed above the PVDF membrane, followed by three stacks of Whatman papers. The 
proteins were then transferred onto three PVDF membrane at 0.6 mA/per blotting stack for 
90 min.  
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3.3.5  Immunoblotting 
To detect the immobilized proteins on the PVDF membrane, we had to label them with the 
appropriate antibody and mark the antibody for chemiluminescence. First, the PVDF 
membrane was blocked with 3 % BSA in TBS for 30 min at RT to prevent non-specific 
binding of antibodies. After the blocking, primary antibody in TBS-T supplemented with 3 % 
BSA was added to the membrane and incubated on a shaking platform for 60 min at RT. 
Afterwards, the membrane was washed three times with TBS-T for 5 min at RT. Then the 
horseradish-peroxidase conjugated secondary antibody (in TBS-T supplemented with 3 % 
BSA) was added and incubated on a shaking platform either for 60 min at RT or 24 h at 4 °C. 
Subsequently, the PVDF membrane was again washed three times with TBS-T for 5 min at 
RT. In order to detect the respective antibody, the PVDF membrane was incubated with 5 ml 
with Pierce® ECL Western Blotting Substrate for 1 min. This solution contains luminol that 
becomes oxidized by the horseradish peroxidase and therefore starts emitting light. This light 
was detected by the Fusion SL detection device. 
3.3.6  RNA isolaton 
For RNA Isolation from cells and EV, the ISOLATE II Biofluids RNA Kit was used and whole 
RNA was isolated according manufactures protocol. Isolated RNA was stored at -80 °C until 
further downstream applications. 
3.3.7  cDNA synthesis 
The RNA was thawed up on ice and concentration was measured using the NanoDrop 
device. For the cDNA synthesis we used the Sensi FAST™ cDNA Synthesis Kit from Bioline. 
1 µg of RNA was used and the DNA synthesis was performed according to the 
manufacturer’s protocol. For the miRNA experiments a different kit was used. Here, the 
miRCURY LNA™ Universal RT microRNA PCR Kit by EXIQON was chosen and the 
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preparations were done according to the manufacturer´s protocol. The cDNA samples were 
finally stored at -20°C for further use.  
3.3.8  RT-PCR of mRNA 
To evaluate the expression of selected mRNA, we performed RT-PCR using the Sybr green 
technology. Therefore, a master mix was prepared containing 1 µg of cDNA (diluted in 
ddH2O), 1 mM of respective forward and reserve primer and 17,5 µl Sybr green (Sensi 
FAST™ SYBR Low-ROX Kit from Bioline). 10 µl of the master mix was transferred as 
triplicates to a 96-well microplate. For the amplification of mRNA the MX3005P qPCR 
System from Stratagene was used.  Amplification program is shown in table 2. 
Step Temperature Duration Cycles 
1 50 °C 2 min 1 
2 95 °C 10 s 42 
3 59 – 63 °C 1 min 42 
4 95 °C 1 min 1 
5 65 °C 30 s 1 
6 95 °C 30 s 1 
Table 2: Program for mRNA amplification 
3.3.9  RT-PCR of mRNA 
To evaluate the expression of selected miRNA, we performed RT-PCR using the Sybr green 
technology. For specific primer binding, we used locked nucleic acid (LNA) primers from 
Exiqon. For this purpose, a master mix was prepared containing 1 µg of cDNA (diluted in 
ddH2O), 3 µl of respective LNA primer  and 17,5 µl Sybr green (Sensi FAST™ SYBR Low-
ROX Kit from Bioline). 10 µl of the master mix was transferred as triplicates to a 96-well 
microplate. For the amplification of mRNA the MX3005P qPCR System from Stratagene 
was.  Amplification program is shown in table 3. 
                                                                                                                                                     
Material and Methods 
41 
 
Step Temperature Duration Cycles 
1 50 °C 2 min 1 
2 95 °C 10 s 45 
3 60 °C 1 min 45 
4 4 °C endless 1 
Table 3: Program for miRNA amplification 
 
3.4  Cell culture 
3.4.1  Isolation of IMC 
We used IMC from the BM to study myeloid cells because of their high amounts in the BM 
and the convenient isolation procedure. IMC were isolated from the tibia and femur of 8 – 12 
weeks old C57Bl/6 mice. Therefore, mice were sacrificed by cervical dislocation and the 
femur and tibia were removed and kept in sterile PBS. Tibia and femur, as well whole cell 
culture procedure was done under the cell culture hood to allow sterile conditions. First, the 
endings of tibia and femur were chopped to have access to the BM. Subsequently, BM was 
flushed out with sterile PBS into a 50 ml conical tube by using a syringe. BM was then filtered 
through a 100 µm cell strainer to separate remaining fat tissue and hair. BM cells were 
washed with PBS at 300 g for 5 min and 4 °C. The supernatant was discarded and 
erythrocytes were lysed with 1 ml Ammonium-Chloride-Potassium (ACK) lysis Buffer for 
3  min at RT. After lysis, BM cells were washed with PBS at 300 g for 5 min and 4 °C. To 
specifically isolate IMC from whole BM cells, we used the MDSC isolation Kit from Miltenyi 
Biotech. This kit specifically isolates Ly-6G and Gr-1 positive cells via magnetic separation. 
First, BM cells were re-suspended in 300 µl MACS buffer and 50 µl FC block reagent was 
added and incubated for 5 min on ice. Then, 100 µl anti-Ly6G-biotin antibodies were added 
an incubated for further 10 min on ice. After Incubation, cells were washed with PBS at 300 g 
for 5 min and 4 °C. Pellet was re-suspended in 800 µl MACS buffer and 200 µl anti-biotin 
MicroBeads and incubated for 15 min on ice. Cells were then washed with PBS at 300 g for 5 
                                                                                                                                                     
Material and Methods 
42 
 
min and 4 °C and cell pellet was re-suspended with 500 µl MACS buffer. Cells were then 
transferred into a LS column on a magnetic rack that was prior equilibrated with 5 ml MACS 
buffer tubes. LS column were washed three times with 3 ml MACS buffer and flow through 
that contained Ly6G negative cells was collected in a 15 ml conical tube. The LS column was 
detached from magnetic rack and 5 ml MACS buffer was applied and flushed out with a 
plunger. Those cells were the Ly-6G positive cells and were kept on ice until further use. 
Next, Ly6G negative cells were taken and washed with PBS at 300 g for 5 min and 4 °C and 
cell pellet was re-suspended with 400 µl MACS buffer and 100 µl anti-Gr1-biotin antibody. 
Cells were stained for 10 min on ice and then washed with PBS at 300 g for 5 min and 4 °C. 
Cell pellet was re-suspended with 800 µl MACS buffer and 200 µl anti-streptavidin 
MicroBeads and incubated for 15 min on ice. Subsequently, cells were washed with PBS at 
300 g for 5 min and 4 °C and cell pellet was re-suspended with 500 µl MACS buffer. Cells 
were then applied on a pre-equilibrated MS column on a magnetic rack, followed by three 
times washing with 500 µl MACS buffer. At the end, MS column was detached from magnetic 
rack and 1 ml MACS buffer was added to the column. Column was flushed out with a plunge 
into the conical which contains the Ly-6G positive cells. The isolated IMC were then stored 
on ice until further use.  
3.4.2  Gating of IMC 
In order to analyze IMC, we needed an appropriate gating strategy. The gating strategy is 
shown in Figure 8. First, forwardscatter (FSC) area (A) was set against sidewardscatter 
(SSC) area (A) to gate IMC, based on their morphology and living state. Afterwards, FSC-A 
against FSC-H was chosen to exclude duplets. Subsequently, CD11b and Gr-1 positive cells 
were gated and checked for their PD-L1 expression. Here, we used the fluorescence minus 
one (FMO) as the border for gating. 
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Figure 8: Gating strategy of isolated IMC 
3.4.3  EV treatment of IMC 
To investigate the effects of Ret-EV on IMC, we cultured the isolated IMC in EV-depleted 
MDSC media. 100.000 IMC in 100 µl media were added to wells of a 96-well plate 
(U-bottom) and treated with 50 ug/ml Ret-EV for either 3 h or 16 h. After incubation with Ret-
EV, IMC were prepared for further analysis 
3.4.4  Co-culture studies 
To investigate Ret-EV mediated upregulation of PD-L1 on IMC, we performed in addition to 
EV treatment experiments, co-culture studies with Ret cells and IMC. The co-culture studies 
were moreover a control to exclude artificial effects of the harsh procedure of 
ultracentrifugation, as well endotoxins. For this purpose, we used a trans-well system. In a 
24-well plate 2.5 x 105 ret cells or fibroblasts were seeded and cultured overnight to assure 
enough secreted EV in the media. To block EV secretion by ret cells, we added 15 µM 
5-(N,N-Dimethyl)amiloride hydrochloride (DMA), an inhibitor of the Na2+/H+ antiporter that 
was shown to reduce EV secretion. Next day, 2.5 x 105 isolated IMC were added above the 
ret cells in a trans-well insert with a pore size of 0.4 µm. The co-culture was incubated 
overnight 37 °C and 5 % CO2 for 24 h and next day, IMC were taken and prepared for flow 
cytometric analysis. 
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3.5  
3.6  Tissue preparation 
3.6.1  Bone marrow 
BM cells were isolated from the tibia and femur of C57Bl/6 mice. Therefore, mice were 
sacrificed by cervical dislocation and the femur and tibia were removed and kept in sterile 
PBS. Tibia and femur, as well whole cell culture procedure was done under the cell culture 
hood to allow sterile conditions. First, the endings of tibia and femur were chopped to have 
access to the BM. Subsequently, BM was flushed out with sterile PBS into a 50 ml conical 
tube by using a syringe. BM was then filtered through a 100 µm cell strainer to separate 
remaining fat tissue and hair. BM cells were washed with PBS at 300 g for 5 min and 4 °C. 
The supernatant was discarded and erythrocytes were lysed with 1 ml Ammonium-Chloride-
Potassium (ACK) lysis Buffer for 3 min at RT. After lysis BM cells were washed with PBS at 
300 g for 5 min and 4 °C and were ready for the staining for flow cytometry. 
3.6.2  Gating of BM cells 
To analyze whole BM, we first excluded duplets by using FSC-A against FSC-H. Afterwards, 
we gated based on the morphology by SSC-A and FSC-A. To exclude dead cells, we gated 
on 7-AAD negative cells. Finally, CD11b and Gr-1 positive cells were gated. 
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Figure 9: Gating strategy for BM cells 
 
3.6.3  Tumor 
As a source for the tumors, we used the transplantable Ret model. Here, we diluted 500.000 
Ret cells in 100 µl sterile PBS. Ret cells were then injected subcutaneously into the right 
flank of mice. During tumor development, tumor growth was monitored and measured with a 
caliper. After 14 days or when tumor reached the size of 1.5 cm in diameter, tumor-bearing 
mice were sacrificed by cervical dislocation. Tumor was extracted and transferred into sterile 
PBS. Afterwards, single cell suspension was prepared by pushing through the tumor tissue 
through 100 µm cell strainer by using a plunge. Tumor cells were washed in PBS at 300 g for 
5 min and 4 °C and again pushed through a 40 µm cell strainer. Subsequently, tumors were 
washed again at 300 g for 5 min and 4 °C and prepared for the staining for flow cytometry.  
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3.6.4  Gating of tumor 
To analyze MDSC in the TME, we used following gating strategy: First duplets were 
excluded by using FSC-A against FSC-H. Next, we gated based on the morphology by using 
SSC-A and FSC-A. To exclude dead cells, we gated on 7-AAD negative cells. To select 
leukocytes in the TME, we gated on CD45 positive cells. Finally, we gated in CD11b and 
Gr-1 positive cells that are MDSC. The Gr-1 higher population represents PMN-MDSC and 
the population underneath represents the monocytic MDSC. 
 
 
Figure 10: Gating strategy of tumor tissue 
3.6.5  Spleen  
Spleen was taken from C57Bl/6 mice. Mice were sacrificed by cervical dislocation, followed 
by the extraction of the spleen. The spleen was transferred into sterile PBS in a 6-well plate 
and mechanically dissociated using scissors and tweezers. Afterwards, spleen fragments 
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were pressed through a 100 µm cell strainer to get single cell suspensions. Subsequently, 
Cells were washed at 300 g for 5 min and 4 °C. Cell pellet was lysed for 3 min at RT by using 
1 ml of ACK lysis buffer. After 3 min, 20 ml PBS was added and cells were washed at 300 g 
for 5 min and 4 °C. Cell pellet was re-suspended in 300 µl MACS buffer and stored at 4 °C 
until further need. 
3.6.6  Adult mouse cardiac fibroblast isolation 
As a control for Ret-EV, we used EV isolated from heart fibroblasts. Heart fibroblasts are 
easy and quick to isolate and produce abundant amounts of EV. For this purpose, adult 
mouse hearts from freshly euthanized mice were placed on Petri dish with sterile ice cold 
PBS, the blood was pumped out with forceps, and hearts were transferred in a clean Petri 
dish. Hearts were minced on ice with scissors, and per each 5 hearts 25ml of lysis buffer 
containing 100 U/ml of collagenase and 0.1 % of trypsin in HBSS were added. Tissue was 
digested in this buffer on constant shaking at 37oC for 10 minutes. Supernatant was collected 
in a Falcon tube, and digestion was continued until tissue was dissolved (7-10 cycles of 
digestion). After centrifugation (300 x g at +4 oC for 5 min), cells were re-suspended (5 ml per 
1 heart) in DMEM/F12 media, containing 10 % FBS and 100 U/ml of PenStrep, and plated 
into 100 mm cell culture dishes (10 ml of cell suspension per dish). After 2 h the media was 
changed, and only fibroblasts were adhered at this time point. Fibroblasts were cultivated 
upon 80- 90 % confluence and split in ratio1:5. After the confluence of 80-90 % was achieved 
again, the isolation of EVs was performed as usual. 
3.6.7  Staining for flow cytometry 
For visualizing the cells via flow cytometry, we had to prior stain them with 
fluorophore-conjugated antibodies or fluorescent chemical compounds. For this, 1x106 cells 
(for tumor cells 3x106 were used) were seeded into a 96-well U-bottom plate and centrifuged 
at 300 g for 5 min 4 °C. Supernatant was discarded and pellet was re-suspended with 100 µl 
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1:100 Fc-Block in FACS buffer and incubated for 10 min on ice. Next, 100 µl FACS buffer 
was added and cells were washed at 300 g for 5 min and 4 °C. Next, master mix containing 
conjugating antibodies and fluorescent chemical compounds were added to stain surface 
antigens, NO, ROS or dead cells. Cells were re-suspended in 50 µl master mix and 
incubated for 30 min on ice in the dark. After staining, cells were washed at 300 g for 5 min 
and 4 °C. Cells were then either re-suspended in 100 µl FACS buffer and ready for flow 
cytometry or if intracellular staining was needed, cells were re-suspended in 200 μL of 
fixation/permeabilization solution (1:4 dilution) (eBioscience) for 30 min at 4 °C in the dark. 
Afterwards, cells were washed twice with 200 μL permeabilization buffer. Subsequently, 
supernatant was discarded and cells were stained with conjugating antibodies targeting 
intracellular antigens for 30 min at 4 °C in the dark. After staining, cells were washed at 300 g 
for 5 min and 4 °C and pellets were re-suspended in 100 μL permeabilization buffer. Finally, 
cells were ready to be measured via flow cytometry.  
3.6.8  Proliferation assay 
To determine the immunosuppressive activity of IMC after EV treatment we performed T cell 
proliferation assays. Here, we treated IMC as mentioned before with Ret-EV and incubated 
them for 16 h. Next day, Ret-EV were washed out twice at 300 g for 5 min at 4 °C. If needed, 
IMC were incubated with neutralizing antibody against PD-L1 for 15 min on ice, followed by a 
washing step. In parallel splenic CD8+ T cells were isolated and prepared for the assay by 
using the CD8+ isolation kit from Miltenyi. As mentioned before, we prepared single cell 
suspensions from spleen and re-suspended splenic cells in 300 µl MACS buffer. 100 µl of 
CD8+ antibody-biotin cocktail was added and incubated for 10 min on ice. Afterwards, 400 µl 
MACS buffer and 200 µl Streptadvidin-MicroBeads were added and incubated for 15 min on 
ice. After staining, 10 ml PBS was added and cells were washed at 300 g for 5 min and 4 °C. 
Supernatant was discarded and cell pellet was re-suspended with 500 µl MACS buffer. Cells 
were then applied on a pre-equilibrated MS column on a magnetic rack, followed by three 
times washing with 500 µl MACS buffer. The flow through was collected, which resembles 
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CD8+ T cells. T cells were centrifuged at 300 g for 5 min and 4 °C and re-suspended in 2 ml 
PBS containing 5 uM Carboxyfluorescein diacetate succinimidyl ester (CFSE). Cells were 
stained at 37 °C for 5 min. Afterwards, 10 ml MACS buffer was added and labeled T cells 
were washed at 300 g for 5 min and 4 °C. T cells were re-suspended in MDSC buffer to a 
concentration of 1.000.000 cells/ml. T cells were then treated with 2 µl per 20.000 T cells with 
pre-washed CD3/CD28 Dynabeads. T cells were then added to IMC in indicated ratios and 
incubated for 72 h. After three days, cells were washed at 300 g for 5 min and FC-Block 
reagent (1:100 in FACS buffer), as well CD8-eFluor antibody (1:100 in FACS buffer) were 
added. After cells were stained for 15 min on ice in the dark, they were washed and re-
suspended in 100 µl FACS buffer, followed by flow cytometry.  
3.6.9  Gating of proliferating CD8+ T cells 
In order to investigate the proliferation of splenic CD8+ T cells, we performed the following 
gating strategy. First, morphology was gated based on FSA-A and FSC-A. Subsequently, we 
gated on CD8 and checked its CFSE intensity. The un-proliferated gate was set according to 
CFSE-labeled CD8+ T cells but without CD2/CD28 activation. 
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Figure 11: Gating strategy for proliferating T cells. 
3.6.10  Interferon- secretion 
Besides testing the suppressive activity of EV-treated IMC in proliferation assays, we 
performed additionally IFN- secretion assays. Here, we used 50 µl of the supernatant from 
the proliferation assay and transferred this supernatant in an IFN- pre-coated NUNC 
Maxisorp 96-well ELISA plate and followed the manufactures instruction. Briefly, the 
supernatant was incubated in the sealed plate for 2 h at RT on a shaking platform. 
Afterwards, plates were washed four times with PBS. Subsequently, 100 µl detection 
antibody was added and incubated for 1 h at RT on a shaking platform. Plate was washed 
four times and 100 µl Av-HRP was added and incubated for 30 min at RT on a shaking 
platform. After washing the plate four times, 100 µl of TMD-substrate was added and 
incubated for 30 min at RT on a shaking platform. Finally, the reaction was stopped by 
adding 100 µl 1 M H2SO4 and absorbance was measured 450 nm within 30 min.  
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3.6.11  Arginase Activity Assay 
In order to measure Arginase 1 activity, we used the Arginase activity assay Kit from Sigma-
Aldrich. Here, we seeded 500.000 IMC into a 24-well plate and treated them with 50µg/ml 
Ret-EV or PBS as a control for 16 h at 37 °C. Next day, cells were taken and lysed with 
100 µl NP-40 lysis buffer for 30 min at 4 °C. Cell lysate was centrifuged for 15 min at 
13.0000 g. Subsequently, 100 µl of supernatant was taken and used for the Arginase activity 
assay, which was performed according to the manufactures protocol. Arginase activity was 
measured at 430 nm and calculated according to manufactures equation. 
3.6.12  Transduction with lentiviral particles 
Lentiviral transduction was kindly performed by Dr. Hüser, DKFZ. Briefly, HEK293T cells 
were used for lentiviral particle production. For transfection, plasmid containing respective 
shRNA (11 µg) was incubated with the packaging plasmids VSV-G (5.5 µg) and pCMV-dR 
8.91 (8.25 µg) in DMEM and X-treme GENE® (Roche) solution for 30 min and added to 
HEK293T producer cells. After incubation for 12, 24, 36 and 48 h, the supernatant was 
collected and virus particles were concentrated by ultracentrifugation. Then Ret cells were 
incubated with concentrated virus for 24 h. Upon the first infection, Ret cells were re-infected 
with the same virus in fresh medium, and after 48 h of transduction, the cells were washed 
twice with PBS and cultured. To select transduced cells, 2 µg/ml puromycin was added for 3 
days.  
3.6.13  Alamar blue assay 
In order to test whether transduced cells were impaired in their proliferation, alamar blue 
assays were performed by Dr. Hüser, DKFZ. Briefly, Ret melanoma cells with stably knocked 
down HSP86 or treated with scrambled sequence shRNA construct were seeded in 96 well 
plates at a density of 2500 cells/well. Alamar blue (10% of the culture medium volume) was 
added after cell attachment for 4 h followed by the measurement of florescence at an 
                                                                                                                                                     
Material and Methods 
52 
 
emission wavelength of 535 nm and an excitation wavelength of 590 nm using a SpectraMax 
M5 microplate reader (Tecan Infinite F200 PRO). Cells were incubated further for 24, 48 and 
72 h; alamar blue was added for the 4 h before the end of each time point and the 
fluorescence was measured. 
3.6.14  Statistics 
Statistical analyses were performed using GraphPad Prism (GraphPad Software) on at least 
3 independent experiments if not indicated differently. Data were analyzed with a one-way 
ANOVA test for multiple groups or an unpaired two-tailed Student´s t test for two groups. A 
value of P < 0.05 was considered as statistically significant. 
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4  Results 
4.1  Characterization of Ret-EVs 
To study the interaction between melanoma-derived EV and the immune system, we 
established a protocol for isolating EV from the murine Ret melanoma cell line (Ret).  
Therefore, we used a modified EV-isolation protocol described by Lobb and Möller [121].   
To verify the quality of our isolated Ret-EV, we performed several quality checks, which are 
in accordance with the guidelines “Minimal experimental requirements for definition of 
extracellular vesicles” [122]. Each batch of Ret-EV was analyzed by nanoparticle tracking 
analysis (NTA). This method measures the concentration and size distribution of particles 
due to their Brownian movement. Figure 7A demonstrates a representative histogram after 
the NTA. Ret-EV are 99.1 nm ± 7.2 nm in diameter and the concentration is 1-5 x 1012 EV/ml. 
Furthermore, we performed Western blot analysis of Ret-EV and the respective Ret cell 
lysate to demonstrate the presence of EV markers. Figure 7B shows that the EV surface 
markers CD9 and CD81 and the intraluminal EV-marker ALIX are strongly enriched in the 
Ret-EV samples. Importantly, we could exclude calreticulin in the Ret-EV preparations. Since 
calreticulin is a protein located in the endoplasmatic reticulum, this result indicates that our 
Ret-EV preparations are free from other organelles and cell debris. As a last quality check, 
CD81-immunogold labeling of Ret-EV was performed in the DKFZ electron microscopy core 
facility. Figure 7C shows a representative snap-shot of Ret-EV. The result shows the 
presence of CD81 on the Ret-EV the size distribution, which is about 100 nm.    
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Figure 12: Characterization of Ret-EV. Ret-EV were isolated by filtration and ultracentrifugation. A) 
Nanoparticle tracking analysis of Ret-EV. B) Representative sample showing the expression of 
EV- markers (CD9, CD81 and ALIX) detected by Western blot analysis. The ER marker calreticulin 
was used as a negative control. C) EV marker CD81 detected by immunogold labeling and electron 
microscopy. 
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4.2  Ret-EV are taken up by myeloid cells 
EV are known to trigger signaling pathways in cells. This could be achieved either by EV 
binding to surface receptors or their uptake by cells, where the transferred cargo can 
stimulate signaling pathways in the cytoplasm. To test whether our Ret-EV are taken up by 
myeloid cells, we treated the immortalized myeloid suppressor cell line (MSC)-1 or IMC with 
CFSE-labeled Ret-EV. Figure 8 demonstrates the uptake of CFSE-labeled RET-EV by 
MSC-1 cells visualized by confocal microscopy (Fig. 8A) and IMC analyzed by flow cytometry 
(Fig. 8B). 
 
 
Figure 13: Uptake of Ret-EV by myeloid cells. Ret-EV were labeled with CFSE and incubated with 
murine MSC-1 cells or BM-derived IMC for 16 h. As a control, we incubated CFSE in PBS with the 
same concentration as Ret-EV. After CFSE labeling Ret-EV and control were ultra-centrifuged to wash 
out residual CFSE. A) The internalization of CFSE-Ret-EV by MSC-1 cells was measured by 
fluorescent confocal microscopy B) and by IMC via flow cytometry. 
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4.3  Ret-EV alters global miRNA expression in IMC 
Recent publication highlighted the EV-mediated conversion of myeloid cells into 
immunosuppressive cells like MDSC or M2 macrophages [84, 123, 124]. Especially, miRNA 
seems to be important for this conversion mediated by tumor-derived EV [125]. To assess if 
RET-EV could induce an immunosuppressive phenotype of IMC by altering their miRNA 
expression pattern, we performed miRNA microarrays. The heat-map (Fig. 9A) and volcano 
plot (Fig. 9B) display a differential expression pattern of distinct miRNA in IMC after Ret-EV 
treatment. In total 119 miRNA are significantly down regulated, whereas 83 are upregulated. 
 
 
 
Figure 14: IMC show altered miRNA expression profile after Ret-EV treatment. IMC isolated from 
the BM of wild type C57BL/6 mice were treated with Ret-EV or PBS for 3 h. After 3 h whole RNA 
content was isolated and miRNA microarray was performed using Agilent chip. A) Heat-map analysis 
and B) Volcano-plot showed different miRNA expression profile of IMC treated with either Ret-EV or 
PBS. 
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By clustering these 202 differentially expressed miRNA in a pathways analyzing tool, we 
found that most of the differentially expressed miRNA are associated with pathways in 
cancers and especially 34 of those miRNA were correlated with melanoma progression 
(Table 2). 
 
miRNA Pathways analysis  
Pathways in cancer                        >90 
PI3K-Akt signaling pathway 46 
Regulation of actin cytoskeleton 42 
MAPK signaling Pathway 42 
TNF Signaling pathway 39 
Melanoma 34 
 
Table 4: Pathways analysis (Diana tools V.5) of IMC treated with Ret-EV. 
 
To verify the miRNA microarray data, we examined via RT-PCR the expression of specific 
miRNA in IMC after Ret-EV treatment. Hereby, we picked miRNA, which were shown to be 
important for MDSC function and biology. Figure 10A confirms the microarray data. All 
chosen miRNA were up regulated, and miRNA 125a and miRNA 690 showed the highest 
upregulation after Ret-EV treatment.  
Besides miRNA, we tested the expression of distinct mRNA from cytokines in IMC after 
Ret-EV treatment, which are known to be produced in high amounts by MDSC. Figure 10B 
demonstrate the upregulation of several cytokines produced by IMC after Ret-EV treatment. 
The pro-inflammatory molecules TNF- and COX-2, as well the anti-inflammatory cytokine 
IL-10 showed the highest upregulation upon Ret-EV stimulation.
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Figure 15: Ret-EV-mediated upregulation of miRNA and cytokines important for MDSC biology. 
IMC isolated from the BM of wild type C57BL/6 mice were treated for 3 h with Ret-EV. Afterwards 
whole RNA was isolated and converted into cDNA. RT-PCR analysis of respective A) miRNA (n=2) 
and B) cytokines show relative expression level of PBS and Ret-EV-treated IMC (mean ± SEM; n=3). 
*p < 0.05, **p < 0.01. 
 
4.4  Production of immunosuppressive factors by IMC treated by Ret-EVs  
In order to test whether Ret-EV can induce the upregulation of known immunosuppressive 
mediators, we treated IMC for 16 h with Ret-EV followed by flow cytometry. Interestingly, we 
could not see a difference in the production of ROS and NO, as well the expression of Arg-1 
between Ret-EV-treated IMC and the control group. (Fig. 11A-C). To confirm that Arg-1 
expression and activity is unchanged, we measured the activity of Arg-1 to catabolize its 
substrate arginine into ornithine.  Figure 11D demonstrate that Arg-1 activity is unchanged in 
IMC upon Ret-EV treatment. 
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Figure 16: Well-known immunosuppressive mediators are unchanged in IMC upon Ret-EV 
treatment. IMC isolated from the BM of wild type C57BL/6 mice were treated with Ret-EV for 16 h. 
Afterwards IMC were stained for flow cytometry A-C) MFI of ROS, NO and Arg-1 from whole IMC 
population is shown. D) Represents Arg-1 activity in Units/l measured by photometrical assay to 
measure Arg-1 activity. (mean ± SEM; n=3) 
4.5  PD-L1 expression on IMC is up regulated after Ret-EV treatment 
Next, we examine the expression of PD-L1 on IMC after Ret-EV treatment. Figure 12A 
demonstrates a representative dot plot measured via flow cytometry. After Ret-EV treatment, 
almost half of the population acquires positivity for PD-L1, whereas the control group (treated 
with PBS) showed only 2-3 % of the population to be positive. To verify if this PD-L1 
upregulation is specific for tumor-derived EV, we isolated treated IMC with EV from cardiac 
fibroblasts (Fibro-EV) and could not detect significant alterations compared to the PBS 
control (Fig. 12B). Interestingly, besides the frequency of PD-L1+ IMC, also the expression 
level of PD-L1 (measured by median fluorescence intensity, MFI) was increased upon Ret-
EV treatment (Fig. 12C). Western blot analysis confirmed the data of flow cytometry (Fig. 
12D). 
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Figure 17: PD-L1 expression is up regulated on IMC after Ret-EV treatment. IMC isolated from 
the BM of wild type C57BL/6 mice were treated with Ret-EV for 16 h. A) Representative dot plots of 
PD-L1 expression on IMC before and after 16 h Ret-EV treatment (including FMO control of Ret-EV 
treated IMC). PD-L1 expression on IMC with Ret-EV or EV isolated from cardiac fibroblasts (Fibro-EV) 
was evaluated by flow cytometry. B) represents the percentage of PD-L1
+
 IMC within total IMC and C) 
the level of PD-L1 expression measured as mean median fluorescence intensity (MFI) D) 
Representative Western blot analysis showing PD-L1 expression in IMC upon Ret-EV treatment. 
(mean ± SEM; n=3). *p < 0.05, **p < 0.01, ***p < 0.001. 
4.6  Co-culture of IMC and Ret cells  
To exclude that the Ret-EV-mediated PD-L1 upregulation on IMC is due to endotoxin 
contamination or side effects of the harsh procedure of ultracentrifugation, we performed co-
culturing studies in the trans-well system. Figure 13A shows the outline of the experimental 
setup. Ret cells or fibroblasts were seeded into wells and above IMC were seeded into trans-
wells. The pore size of the trans-wells were 0.4 µm in size, excluding thereby a direct cell to 
cell contact and allowing only soluble factors and EV to circulate.  Figure 13B and C show 
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that only Ret cells up regulate the expression of PD-L1 on IMC, whereas fibroblasts do not 
show a significant effect on PD-L1 expression on IMC. To prove if the PD-L1 upregulation is 
due to EV, we co-cultured Ret cells in media supplemented with dimethyl-amiloride (DMA), 
an H+-antiporter inhibitor that was shown to indirectly block the secretion of EV [126]. The 
addition of DMA into the co-culture system significantly reduced PD-L1 upregulation, 
suggesting that EV play a major role in the induction of PD-L1 on IMC.   
Figure 18: Trans-well studies confirm the Ret-EV-mediated PD-L1 up regulation on IMC. A) Ret 
cells or fibroblasts were co-incubated with IMC for 24 h using a 0.4 µm trans-well system. The analysis 
of PD-L1 expression on IMC was performed by flow cytometry. B) Data are shown as the percentage 
of PD-L1
+
 IMC among total IMC and C) the level of PD-L1 expression as MFI (mean ± SEM; n=4) *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
4.7  Ret-EV mediated PD-L1 upregulation occurs in vivo 
Next we address the question if Ret-EV could mediate PD-L1 upregulation also in vivo. For 
this, we genetically modified the Ret cell line by transducing a construct that overexpress 
GFP-coupled to CD81. This CD81-fusion protein should be included into EV, since CD81 is a 
predominant protein in EV. The uptake of CD81-GFP+ EV by recipient cells makes it possible 
to visualize them via flow cytometry and to follow EV uptake in vivo (Fig. 14A). We injected 
subcutaneously the modified Ret cells into C57Bl/6 mice. After 14 days of tumor 
development, we sacrificed tumor-bearing mice and found CD81-GFP+ MDSC (Fig. 14B). 
Those MDSC showed a tendency to have higher expression levels of PD-L1 (Fig. 14C). This 
data highlights the importance of Ret-EV-mediated PD-L1 up regulation in vivo and confirms 
in vitro effects.   
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Figure 19: Ret-EV mediated upregulation occurs in vivo. A) Demonstrates a schematic overview 
of the experiment. GFP is linked to CD81 that is incorporated into EV. EV are released by tumor cells 
and recipient cells take up the GFP-labeled tumor-derived EV. Ret cells were transduced with vector 
expressing CD81 linked to GFP or control vector. B-C) Transduced cells were injected subcutaneously 
into C57BL/6 mice. Upon 14 days of tumor growth, mice were sacrificed and single cell suspension 
from tumor tissue was made followed by staining for MDSC. Stained samples were measured by flow 
cytometry. B) Representative dot plots for GFP expression in tumor-infiltrating CD11b
+
Gr1
+
 are 
shown. C) Expression of PD-L1 on GFP
+
 MDSC was presented as MFI (mean ± SEM; n=3). 
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4.8  Ret-EV convert IMC into immunosuppressive cells 
To test whether Ret-EV convert IMC into immunosuppressive cells, we performed T cell 
proliferation assays with Ret-EV treated IMC. After 16 h of incubation, we washed out Ret-
EV twice and added CFSE-labelled splenic CD8+ T cells to the IMC. After three days, we 
measured the proliferation rate of the T cells via flow cytometry and found a decreased 
proliferation rate of CD8+ T cells. The inhibition of proliferation was dependent on the ratio 
between Ret-EV treated IMC and CD8+ T cells. As expected, we did not observe alterations 
in proliferation when we cultured PBS-treated IMC with activated CD8+ T cells or CD8+ T cells 
alone (Fig. 15A). To elucidate if PD-L1 was the major immunosuppressive mediator, we 
blocked PD-L1 via neutralizing antibody and observed that the proliferation rate was almost 
completely restored when blocking PD-L1 on IMC treated with Ret-EV (Fig. 15B). Besides 
the proliferation rate, we measured the secretion of IFN- by CD8+ T cells as an indicator for 
their activity. Similar to the proliferation rate, Ret-EV treated IMC were able to dampen the 
IFN-production, which was restored upon blocking PD-L1 on IMC. Our data indicates that 
PD-L1 upregulation on Ret-EV-treated IMC is the major driver for their immunosuppressive 
activity.  
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Figure 20: EV-treated IMC show immunosuppressive capacity mediated by PD-L1. IMC isolated 
from the BM of C57BL/6 mice were incubated with Ret-EV for 16 h. After washing out the rest of EV, 
cells were treated with PD-L1 neutralizing or isotype control mAbs (Iso) for 15 min followed by the co-
incubation with normal spleen CD8
+
 T cells labeled with CFSE and stimulated with anti-CD3/CD28 
Dynabeads for 72 h. T cell proliferation was evaluated by CFSE dilution by flow cytometry. A) 
Inhibition of CD8
+
 T cell proliferation by EV-treated IMC at indicated IMC:T cell ratio. Data are 
presented as the percentage of divided T cells (mean ± SEM; n=6). B) Proliferation and C)  
IFN-secretion of stimulated CD8
+
 T cells upon blocking PD-L1 expression on IMC (IMC:T cell 
ratio=1:1;  mean ± SEM; n=3). *p < 0.05, **p < 0.01. 
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4.9  PD-L1 in Ret-EV is not transferred to recipient cells 
Next, we investigate if PD-L1 upregulation is due to the transfer of PD-L1 on Ret-EV to 
recipient cells or is achieved by new synthesis of PD-L1. As shown by Western blot analysis 
Ret cells strongly express PD-L1 and moreover, Ret-EV also displayed some expression of 
PD-L1 (Fig. 16A). To study the mechanisms of Ret-EV-mediated PD-L1 upregulation, we 
used MSC-1 and MSC-2 cells. The treatment of MSC-2 with Ret-EV induced an upregulation 
of PD-L1, whereas MSC-1 did not show such effect (Fig. 16B). We could exclude that MSC-1 
cells are incapable to take up Ret-EV as we proved it before (Fig. 8A). To test whether 
PD-L1 upregulation is due to its new synthesis, we treated MSC-2 cells with actinomycin-D 
(an inhibitor of RNA synthesis) prior Ret-EV treatment. As shown in Figure 16C, MSC-2 cells 
treated with actinomycin-D did not show an induction of PD-L1, indicating that PD-L1 new 
synthesis is induced upon Ret-EV treatment, whereas transfer of vesicular PD-L1 plays a 
minor role. 
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Figure 21: PD-L1 is not transferred via vesicular transport. A) Representative Western blot of 
PD-L1 in Ret-lysate and Ret-EV. B) MSC-2 and MSC-I cells were treated with Ret-EV and PD-L1 
expression was determined after 16 h via Western blot. C) MSC-2 cells were treated with the RNA 
synthesis inhibitor actinomycin-D followed by Ret-EV incubation for 16 h. Ret cells were lysed and 
PD-L1 expression was determined via Western blot analysis. 
4.10  PD-L1 upregulation is induced by NF-B activation 
Recent studies showed that tumor-derived EV induce the phophorylation of NF-B promoting 
an inflammatory response [127]. Western blot analysis verified that Ret-EV stimulate the 
phophorylation of NF-B in a time-dependent manner (Fig. 17A). After 30 min of incubation, 
MSC-2 cells showed a strong activation of NF-B with a maximum at 5 h followed by the 
reduction of NF-B activation upon 10 h. To find out if NF-B was crucial for the Ret-EV 
mediated PD-L1 upregulation, we treated MSC-2 cells with the NF-B inhibitor BAY11-7082 
(Bay) prior the incubation with Ret-EV. PD-L1 expression intensity on MSC-2 cells was found 
to be decreased (Fig. 17A). To test if IMC also activates NF-B upon Ret-EV treatment, we 
performed intracellular staining of phoshporylated NF-B after 30 min of Ret-EV treatment. 
Flow cytometry data confirmed the activation of NF-B in IMC after Ret-EV treatment (Fig. 
17C). Importanly this activation was almost as strong as using LPS, a known inducer of 
NF-B signaling in myeloid cells. 
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Figure 22: PD-L1 up-regulation induced by Ret-EV is mediated by NF-B activation. A) Time 
dependent accumulation of pNF-B in MSC-2 cells under the treatment with Ret-EV detected by 
Western blot. B) MSC-2 cells were treated with the NF-B inhibitor Bay followed by Ret-EV incubation 
followed by flow cytometry. Results are presented as the level of PD-1 expression on MSC-2 
measured as MFI (mean ± SEM; n=4). C) IMC isolated from the BM of C57BL/6 mice were incubated 
with Ret-EV for 16 h and pNF-B was stained and measured by flow cytometry. Results are presented 
as MFI of whole IMC population. (mean ± SEM; n=4) *p < 0.05, **p < 0.01. 
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4.11  TLR agonists induce NF-B activation in myeloid cells 
TLR signaling is a known inducer of the NF-B pathway [91]. Furthermore, many studies 
showed that tumor-derived EV stimulated cells via different TLR [126-128]. To test weather 
MSC-1 and MSC-2 cells are activated upon TLR signaling, we treated them with TLR2, TLR4 
and TLR7/8 agonists and measured NF-B activation via Western blot. All TLR agonists 
could stimulate NF-B activation on both MSC cells (Fig 18). The TLR2 agonist Pam3/CSK4 
induced a strong NF-B activation already after 30 min, which was lasting up to 10 h of 
incubation
agonist in MSC-2 cells but it differs in MSC-1 cells, in which only a weak phosphorylation of 
NF-B was observed after 30 min. The activation diminished after 3 h. In contrast, TLR7 
agonist R848 did not show an induction of NF-B in MSC-2 cells, whereas a very slight 
activation could be observed in MSC-1 cells after 1 h, which diminished after 5 h. Taken 
together, our results underline the importance of TLR signaling in myeloid cells. TLR agonists 
are able to induce NF-B activation in a time-dependent manner, which also shows 
differences in different types of myeloid cells.  
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Figure 23: TLR agonist stimulate activation of NF-B in MSC cell lines. MSC-1 and MSC-2 cells 
were treated with respective TLR agonist for indicated time. MSC cells were lysed afterwards and 
pNF-B was detected by Western blot analysis. 
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4.12  PD-L1 upregulation is induced by MyD88-dependent TLR signaling 
Stimulation with TLR agonist showed a similar NF-B activation kinetics as Ret-EV did on 
MSC-2 cells. To test whether Ret-EV dependent PD-L1 upregulation on IMC is dependent on 
TLR signaling, we investigated Myd88–/– and Myd8–/–/Trif–/– mice. We isolated IMC from 
wild type and both knockout mice and treated them with Ret-EV as described before. 
Interestingly, we determined that the upregulation of PD-L1 was almost completely 
dependent on the MyD88 pathway. The frequency of PD-L1+ IMC (Fig. 19A) and the 
expression level of PD-L1 on PD-L1+ IMC (Fig. 19B) did not show any significant difference 
between Ret-EV treated and PBS-treated IMC. The double knock-out mice showed similar 
results as the Myd88–/– mice. Therefore, MyD88-dependent TLR signaling could be the main 
mechanism of the Ret-EV mediated PD-L1 upregulation on IMC. 
 
 
 
Figure 24: Ret-EV induced PD-L1 upregulation is mediated by the MyD88 dependent TLR 
pathway. IMC were isolated from the BM of mice deficient for MyD88 or for MyD88 and TRIF followed 
by incubation for 16 h followed by flow cytometry. A) Data are shown as the percentage of PD-L1
+
 
IMC within total IMC or B) the level of PD-L1 expression as MFI (mean; n=2). 
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4.13  TLR4 signaling is the main driver for PD-L1 upregulation 
To figure out which TLR is responsible for the Ret-EV mediated PD-L1 upregulation, we 
study the expression of TLR on IMC. We could determine high amounts of TLR7 and as well 
traceable amounts of TLR2 and TLR4 (Fig. 20A). Next, we investigated if the TLR are also 
functional. Therefore, we treated IMC with TLR2 (Pam3CSK4), TLR4 (LPS) and TLR7/8 
(R848) agonists and found that all TLR agonist induced a strong PD-L1 upregulation on IMC 
(Fig. 20B). Next, we isolated IMC from Tlr2-/-, Tlr4-/- and Tlr7-/-mice and treated them with 
Ret-EV. All TLR deficient IMC showed impaired PD-L1 induction compared to wild type IMC. 
We compared the percentage of PD-L1+ IMC in knock-out IMC compared to wild type IMC 
(Fig. 20C). The data revealed that TLR4 is mostly responsible for the PD-L1 induction on 
IMC. This data concludes that TLR signaling is indeed involved in the Ret-EV mediated 
PD-L1 upregulation. However, it seems that many TLR could play a role with the 
predominance of TLR4. The frequency of PD-L1+ IMC isolated from Tlr4-/- mice increased 
after Ret-EV treatment from 4.37 % up to 14.73 %, whereas IMC from wild type mice 
increased from 7.03 % to 54.13 %. We could see the same elevation for the intensity level of 
PD-L1 expression (Fig. 20E). Moreover, we checked if in IMC from Tlr4-/- mice, new 
synthesis of PD-L1 is induced. As seen in Figure 20F, we could not see any differences 
between stimulated and unstimulated TLR4-deficient IMC, whereas wild type IMC showed 
higher PD-L1 mRNA transcription. Confirming our hypothesis, performing inhibition of T cell 
proliferation assays, revealed that IMC from Tlr4-/- mice were not able to inhibit T cell 
proliferation (Fig. 20F). Taken together, TLR signaling, especially TLR4 is essential for the 
transcription of PD-L1 mRNA in IMC. 
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Figure 25: Ret-EV mediated PD-L1 upregulation is triggered mostly by TLR4 signaling.  A) IMC 
were isolated from the BM of wild type and the intensity of indicated TLR was measured via flow 
cytometry B) IMC were treated with respective TLR agonist and PD-L1 upregulation was  measured 
via flow cytometry. PD-L1 expression is presented as the percentage of PD-L1
+
 IMC within total IMC 
C) IMC were isolated from the BM of wild type and TLR-deficient C57BL/6 mice and treated with 
Ret-EVs for 16 h followed by flow cytometry. C) PD-L1 expression is presented as the percentage of 
PD-L1
+
 IMC within total IMC or D)  as the level of PD-1 expression on IMC measured as MFI (mean ± 
SEM; n=4). E) Expression of PD-L1 in wild type and Tlr4
-/- 
IMC measured by RT-PCR and normalized 
to 18s RNA F) Inhibition of CD8
+
 T cell proliferation by wild type and TLR4
-/-
 IMC treated with Ret-EV 
(IMC:T cell ratio = 1:1??). Data are presented as the percentage of divided T cells (mean ± SEM; 
n=6). *p < 0.05, **p < 0.01. 
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4.14  Ret-EV educated mice develop tumors faster  
Several studies showed that mice treated with tumor-derived EV can display accelerated 
tumor growth [126, 129]. Here, we injected every second day 50 µg of Ret-EV 
intraperitoneally into C57BL/6 mice. On day 5, we injected Ret cells into the flank and 
monitored tumor growth for 14 days. Our results demonstrated a Ret-EV mediated 
acceleration of tumor growth (Fig. 21A). In contrast, when we perform the aforementioned 
experiments in Tlr4-/- mice, Ret-EV pretreatment failed to accelerate the tumor growth (Fig. 
21B).  
 
 
 
Figure 26: Educating mice with Ret-EV promotes tumor growth in wild type mice but not in 
TLR4-deficient mice. Ret-EV or PBS were injected each second day into wild type or Tlr4
-/-
 mice. On 
day 5, Ret cells were injected subcutaneously into the flank. A) Tumor progression was monitored for 
14 day and B) tumor was weight on day 14 after mice were sacrificed (mean ± SEM; n=3) *p < 0.05. 
 
 
 
 
 
 
 
     Results 
75 
 
4.15  Ret-EV express high amounts of HSP86 
Next, we aim to decipher the ligands for the Ret-EV mediated TLR4 signaling. Several 
ligands on tumor-derived EV were previously shown to induce TLR2 and TLR4 signaling 
[126, 130]. Figure 22A demonstrates that HSP86 that was previously shown to mediate 
TLR2/4 signaling [131-133], is strongly expressed in all Ret-EV preparations. We found also 
small amounts of HSP72 on Ret-EV. HSP72 on tumor-derived EV was previously reported to 
exert immunosuppressive properties on myeloid cells [126, 130, 134]. HMGB1 and HSP60 
were absent on our preparations, whereas cells showed a high expression of both proteins. 
S100A8 and S100A9 were also described to be a potent inducer of TLR4 signaling, however, 
we failed to detect these proteins in Ret-EV and Ret cell lysate (data not shown). Next, we 
investigated the localization of HSP72 and HSP86 on Ret-EV. Therefore, we coupled Ret-EV 
on latex-beads. By this technique, it is possible to measure EV by flow cytometry. Figure 22B 
demonstrates that HSP72 and HSP86 are expressed on the surface of Ret-EV, with higher 
intensity of HSP86, which confirm the results of Western blot. 
 
Figure 27: Ret-EV carry high amounts of HSP86 and HSP72.  A) Different batches of Ret-EV were 
lysed and indicated proteins were analyzed by Western blot. B) Ret-EV were coupled onto latex beads 
and stained for indicated HSP. HSP expression level was measured via flow cytometry. Black line 
indicates the secondary antibody control and blue - the expression of indicated HSP. 
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4.16  Inhibition of inducible HSP abrogate Ret-EV-mediated PD-L1 induction  
Next, we treated Ret cells with KNK-437, a potent inhibitor of the transcription of inducible 
HSP [135]. Upon the treatment with higher concentration of KNK-437, Ret cells showed a 
reduced expresssion of HSP72 and HSP86 (Fig. 23A). Then, we isolated EV from Ret cells 
treated with 500 nM KNK-437 or DMSO and measured the quantity and size distribution of 
both EV types. KNK-EV or DMSO-EV (Ret-EV) did not show differences in terms of quantity 
and size distribution (Fig. 23B and C), indicating that KNK-437 does not effect the EV 
secretion by Ret cells. We found that EV isolated from KNK-437-treated Ret cells were 
incapable to induce PD-L1 upregulation on murine IMC, whereas EV from control Ret cells 
could upregulate PD-L1 expression (Fig. 23D and E). Taken together, inhibiting the synthesis 
of inducible HSP impairs the Ret-EV mediated upregulation of PD-L1 on IMC. Since we 
could not fully exclude any contamination of KNK-437 in the isolated Ret-EV preparations, 
additional controls should be included.     
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Figure 28: HSP86 is critical for Ret-EV mediated PD-L1 upregulation on IMC. A) Ret cells were 
treated with the indicated concentrations of KNK-437. After 24 h Ret cells were lysed and proteins 
were isolated. The expression of HSP86 in cell lysates was analyzed by Western blot. B-C) NTA of 
KNK-EV and Ret-EV showing the size distribution and concentration of EV. D) IMC were treated with 
Ret-EV isolated from KNK437-treated (KNK-EV) or untreated Ret cells (RET-EV). PD-L1 expression 
was determined by flow cytometry and shown as the percentage of PD-L1
+
 IMC among total IMC or E) 
as the level of PD-1 expression as MFI. (mean ± SEM; n=3) *p < 0.05, **p < 0.01, ***p < 0.001. 
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4.17  HSP86-deficient Ret cells are unable to induce PD-L1 on IMC 
To evaluate if inducible HSP are responsible for the Ret-EV mediated PD-L1 upregulation on 
myeloid cells, we stably knocked-down HSP86 in Ret melanoma cells (Fig. 24A). We chose 
construct #6 for the trans-well experiments, which revealed that HSP86-deficient Ret cells 
displayed impaired PD-L1 upregulation on IMC upon their co-culture (Fig. 24B). The 
frequency of PD-L1+ IMC and PD-L1 intensity on PD-L1+ IMC was lower as compared to co-
culturing with the scramble shRNA control (Fig.24 C), suggesting a critical role of HSP86 in 
the observed PD-L1 upregulation on IMC.  
  
Figure 29: HSP86 is crucial for Ret-EV mediated PD-L1 upregulation. HSP86 on Ret cells were 
stably knock-down by lentiviral transduction. A) Western blot analysis demonstrates the efficiency of 
HSP86 knock-down and respective scramble control. B-C) shSCR or shHSP86 Ret cells were co-
cultured with wild type IMC in a trans-well assay for 24 h. Data on are shown as B) the percentage of 
PD-L1
+
 IMC and C) level of PD-L1 expression as MFI. (mean ± SEM; n=3) *p < 0.05, **p < 0.01. 
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4.18 Depletion of HSP86 in Ret melanoma cells impairs tumor growth and 
reduces PD-L1 expression on MDSC 
To study the impact of HSP86 expression in tumor cells on their growth in vivo, we injected 
HSP86-deficient Ret cells (shHSP86) and their respective scramble control (shSCR) 
subcutaneously into C57BL/6 mice. We monitored tumor growth for 14 days (Fig. 25A). It 
was found that HSP86-deficient Ret cells grow slower than shSCR counterpart, which 
reached the endpoint (tumor size 1.5 cm) already 14 days after their injection. We found also 
a strong tendency for decreased tumor weight in mice injected with shHSP86 cells (Fig. 
25B). To exclude that HSP86-deficient Ret cells have impaired proliferation capacity, we 
tested it via alamar blue assay and found no difference between shHSP86 and shSCR Ret 
cells (Fig. 25C).  
In addition, shHSP86 tumors showed decreased frequency of MDSC in the TME (Fig. 25D). 
Furthermore, we found a decreased frequency of PD-L1+ MDSC in tumors of mice injected 
with shHSP86 Ret cells. In addition, MDSC showed lower expression level of PD-L1 in 
HSP86 deficient tumors compared to the respective control (Fig. 25F). Analyzing the BM, we 
observed no changes in the frequency of MDSC between both experimental groups (Fig. 
25G). However, we could measure a significant reduction in the frequency of PD-L1+ MDSC 
(Fig. 25D) and in the intensity of PD-L1 expression (Fig. 25I) in mice injected with HSP86-
deficient Ret cells.  
Taken together, the absence of HSP86 expression in tumor cells and tumor-derived EV 
leads to a less immunosuppressive TME due to reduced frequencies of MDSC and PD-L1 
expression on these cells. 
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Figure 30: Reduced growth of HSP86-deficient Ret cells in vivo. HSP86-deficient Ret cells 
(shHSP86) or scramble control (shSCR cells) were injected subcutaneously into C57BL/6 mice. Tumor 
growth was monitored for 14 days in both tumor bearing mice.  A) Kinetics of tumor growth is shown. 
B) Tumor weight was measured on day 14 after mice were sacrificed. C) shHSP86 Ret cells and 
shSCR Ret cells were incubated with alamar blue, and their metabolic activity was measured via 
spectrometry.  D-I) At day 14, tumor and BM single cell suspensions were analyzed by flow cytometry. 
D-F) Data on tumor infiltrating MDSC are shown as the percentage among total leukocytes (D). PD-L1 
expression is presented as E) the percentage of PD-L1
+
 MDSC in tumors and F) level of PD-1 
expression as MFI. G-I) Data on BM MDSC are shown as the percentage of these cells among total 
leukocytes (G). PD-L1 expression is presented as F) the percentage of PD-L1
+
 MDSC in BM and I) 
level of PD-1 expression as MFI (mean ± SEM; n=4). *p < 0.05.
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5  Discussion 
Malignant melanoma is a therapy-resistant and very aggressive type of cancer [1]. One 
major reason for this is the accumulation of highly immunosuppressive myeloid cells, mainly 
MDSC, in the TME. The hallmark of MDSC biology is the suppression and inactivation of 
effector T cells through numerous mechanisms [46]. One of these is the upregulation of 
PD-L1 expression on MDSC. To date, many pathways were described to be important for 
PD-L1 upregulation [66]. However, most pathways are linked with the induction by soluble 
factors and only little is known about EV-mediated upregulation of PD-L1 on myeloid cells 
and how tumor-derived EV can reprogram IMC into immunosuppressive cells. Unveiling the 
mechanisms of the conversion of myeloid cells into immunosuppressive cells by tumor-
derived EV could help finding new targets for cancer immunotherapy. 
5.1  Quality and characteristics of Ret-EV  
Proliferating tumor cells secrete high amounts of EV, which are distributed systematically 
through the body [136]. Those EV are taken up by many cell types, which in turn influence 
their activity and metabolism [75, 76, 78, 137, 138]. During the last years, accumulating data 
highlighted that tumor-derived EV reprogram the host cells into a more tumor-supporting 
phenotype [139]. Ridder et al. (139) showed that tumor-derived EV were taken up in vivo 
preferentially by myeloid cells in the TME. Those myeloid cells showed a more 
immunosuppressive phenotype due to their uptake of tumor-derived EV in vivo. To study the 
underlying mechanism of this reprogramming, it is essential to isolate pure and functional 
tumor-derived EV that are free from organelles and cell debris. 
Using our modified protocol, adopted from Lobb and Möller [121], we could demonstrate that  
Ret-EV preparations fulfill all the minimal requirements to define them as pure EV [122]. First 
of all, NTA analysis visualized the size distribution of our Ret-EV that was approximately 100 
nm in diameter and correlated with the size attributed to small EV, mainly exosomes. This 
size-distribution was confirmed by immunogold labeling of CD81 on the Ret-EV. In addition, 
we showed that the EV-surface marker CD81 and CD9 as well the intraluminal marker ALIX 
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was present in Ret-EV preparations, whereas Ret-EV were negative for the endoplasmatic 
reticulum marker calreticulin.   
5.2  Expression of PD-L1 on Ret-EV   
Interestingly, we found that Ret-EV were positive for PD-L1. This indicates that Ret-EV could 
act directly suppressive on activated T cells, when encountering them. Indeed, previous 
studies demonstrated the suppressive potential of PD-L1 expressing EV [140]. In melanoma 
patients, the level of circulating-PD-L1 positive EV correlated with IFN-in the plasma [141]. 
Those circulating melanoma-derived PD-L1-positive EV were shown to suppress T cells and 
to mediate immune evasion. Furthermore, PD-L1-positive EV were associated with the 
response of anti-PD-1 therapy. In a similar fashion, Ricklefs et al. [140] showed that patients 
suffering from glioblastoma produced high amounts of PD-L1 positive EV that suppress 
antitumor immunity and led to immune evasion of glioblastomas.  
Next to PD-L1 also Fas ligand (FasL) was found on tumor-derived exosomes [142]. It has 
been shown that EV isolated from the body fluids of acute myelogenous leukaemia patients 
induced apoptosis in T cells that was mediated by Fas/FasL signaling [142]. In addition, 
studies described that EV isolated from LNCaP, a human prostate cancer cell line, induced 
Fas/FasL driven apoptosis in T cells [143]. FasL on EV was also found to promote tumor 
growth in an apoptosis independent fashion [144]. In this study, EV-derived from activated T 
cells were isolated from tumor-bearing mice. Those EV expressed FasL but had little effect 
on the apoptosis of tumor cells. Instead, FasL promoted the ERK and NF-B pathway, which 
subsequently increased the expression of MMP9 in the TME. This led to a more aggressive 
invasion of tumor cells. Using blocking antibodies against FasL, the migration capacity of 
tumor cells was significantly reduced.        
We did not study here the direct immunosuppressive effect of Ret-EV on effector CD8+ T 
cells but focused on the Ret-EV educated immunosuppression of myeloid cells, in particular 
MDSC. However, it is important to keep in mind that PD-L1+ EV could also exhibit direct 
immunosuppressive properties on effector CD8+ T cells. 
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5.3  Ret-EV promote tumor progression by inducing PD-L1 expression on 
myeloid cell 
Initial studies reported that tumor-derived EV could be a source of tumor-associated antigens 
and therefore, they could activate the immune system and stimulate a T cell-mediated anti-
tumor response [145]. However, pioneering work by Taylor and Black in 1985 indicated that 
vesicles shed by melanoma cells could also have immunosuppressive properties [146]. In 
their study, they showed that melanoma-derived vesicles inhibit the upregulation of co-
stimulatory molecules on murine macrophages. However, the conversion of myeloid cells 
into immunosuppressive cells was still under discussion. Only 21 years later Valenti et al. 
(146) demonstrated that melanoma-derived EV converted monocytes into TGF- secreting 
myeloid suppressive cells, which was accompanied by the loss of human leukocyte antigen 
(HLA) class II expression. Furthermore, they showed that EV-educated monocytes were able 
to reduce the lytic activity of effector CD8+ T cells. Since then, the interest to the 
immunosuppressive properties of tumor-derived EV increased dramatically. In the last 10 
years, many studies reported a tumor-promoting effect of tumor-derived EV rather than an 
anti-tumorigenic effect. Thus tumor-derived EV were reported to drive the formation of pre-
metastatic niches [52, 80], immunosuppressive microenvironment [139] and as well 
promoting migratory and invasiveness of tumor cells [147-149].  
In this study, we could prove that Ret-EV convert IMC from the BM into immunosuppressive 
MDSC by upregulating inflammatory cytokines and PD-L1 expression. This 
immunosuppression was systemic as we found a strong PD-L1 upregulation in the TME and 
in the BM of tumor-bearing mice. Such upregulation of PD-L1 was reduced when we injected 
tumor cells deficient in HSP86, which was found to be a predominant mediator of PD-L1 
upregulation in this study. Similarly, Haderk et al. (128) reported that EV isolated from the 
plasma of chronic lymphocytic leukemia patients induced a strong upregulation of PD-L1 in 
circulating CD14+ monocytes. This upregulation was due to the loading of the non-coding Y 
RNA hY4 into patients’ EV, whereas EV isolated from healthy donor showed less amounts of 
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this non-coding RNA. Further studies investigated the role of EV isolated from hepatocellular 
carcinoma cells, showing that tumor-derived EV upregulated PD-L1 on human monocytic cell 
line THP-1 and murine macrophages [150]. The authors did not describe the mediator of this 
induction. However, since they found the reduction of PD-L1 stimulation by treating tumor 
cells with melatonin that was earlier reported to decrease the induction of several HSP after 
oxidative stress [151], we believe that HSP86 on tumor-derived EV might trigger PD-L1 
expression also in their system. 
Recently, it was reported that EV isolated from glioblastoma stem cells could reprogram 
monocytes into immunosuppressive M2 macrophages [123]. This conversion was associated 
with PD-L1 upregulation. Using mass spectrometry the group identified components in the 
tumor-derived EV that induce the STAT3 pathway in treated monocytes. In our study, we 
found also EV-dependent STAT3 activation. It seems that EV from different tumor types use 
similar mechanisms to induce an immunosuppressive microenvironment.  Studying the effect 
of tumor-derived EV on DC, Ning et al. (152) could show that tumor-derived EV blocked the 
differentiation of progenitor DC into fully matured DC and furthermore, those DC showed 
immunosuppressive capacities as priming of T cells led to decreased amounts of IFN- 
production. Interestingly, when the authors blocked PD-L1 on EV-treated DC, the 
immunosuppressive properties were strongly decreased. This data highlights the important 
role of EV-mediated PD-L1 upregulation also on other myeloid cell subsets. 
5.4  Ret-EV promote tumor progression by inducing MDSC 
Besides, upregulating PD-L1 on myeloid cells, tumor-derived EV use further mechanism to 
convert normal myeloid cells into pro-tumorigenic cells. We could demonstrate that tumor-
derived EV stimulated the production of miRNA and cytokines associated with MDSC biology 
and function. We have observed a strong upregulation of IL-6, Cox-2 and TGF-. In line with 
our data, Xiang et al. [152] showed that treating myeloid cells with tumor-derived EV 
enhanced the secretion of IL-6, Cox-2, VEGF and TGF- in vitro. By blocking vesicular 
TGF- and PGE2, the differentiation of BM myeloid cells into MDSC was inhibited. 
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Furthermore, they could show that educating naïve mice with tumor-derived EV led to 
expansion of MDSC that correlated with the growth of TS/A tumor cells. Peinado et al. (129) 
demonstrated that melanoma-derived EV educated BM progenitor cells towards a pro-
metastatic phenotype promoted by the MET receptor. Highly metastatic melanoma cells sort 
the c-MET oncogene into EV. Those melanoma-derived EV are taken up by BM cells that 
lead to BM cells with a pro-vasculogenic and pro-metastatic phenotype. Using EV from non-
metastatic melanoma cells or directly reducing MET expression in EV, resulted in reduced 
pro-metastatic behavior of BM cells. Chalmin et al. (126) also observed the differentiation of 
BM cells into MDSC. They described that EV-mediated expansion of MDSC was due to 
HSP72 on tumor-derived EV. HSP72 was shown to trigger TLR2/MyD88 and STAT3 
signaling in BM cells, leading to increased production of IL-6. EV-treated IMC acquired 
immunosuppressive functions upon EV-treatment proved by T cell proliferation assays 
similar to our studies. Interestingly, by blocking EV secretion in vivo by DMA or omeprazole, 
they observed less MDSC was observed in the TME and tumor growth was significantly 
slowed down. Similar studies were performed in models for multiple myeloma [152, 153]. EV 
isolated from multiple myeloma cell lines stimulated the expansion of MDSC in vitro and 
converted IMC into MDSC in the BM. The conversion and expansion were found to activate 
STAT3 signaling. By testing their immunosuppressive potential, the authors could prove the 
immunosuppressive properties of MDSC by inhibition of T cell proliferation. Contrary to our 
studies, they associated the increased immunosuppressive capacity with increased levels of 
iNOS. Upon the treatment with tumor-derived EV a more resistant to apoptosis phenotype 
was observed. This was linked to increased STAT1 and STAT3 activation that in turn 
activated the anti-apoptotic proteins B-cell lymphoma-extra-large (Bcl-xL) and induced 
myeloid leukemia cell differentiation protein (Mcl)-1. Further studies reported that EV isolated 
from pancreatic ductal adenocarcinoma (PDAC) cell lines induced MDSC expansion in the 
TME [154]. This expansion was dependent on mothers against decapentaplegic homolog 
(SMAD)-4 signaling which increased calcium influx and glycolysis in myeloid cells [155-157]. 
SMAD-4 signaling was found to be induced by miRNA-494 and miRNA-1260 transferred by 
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PDAC-derived EV. Furthermore, tumor-derived EV were shown to stimulate an 
immunosuppressive TME due to their mutation in p53 [124]. P53-mutated tumors selectively 
produced EV enriched with miRNA-1246 that induced polarization of macrophages into a M2 
phenotype. Those reprogrammed macrophages were shown to be more pro-tumorigenic and 
anti-inflammatory after EV treatment from p53 mutated tumor cells.  
The potential to induce immunosuppressive DC by EV were also intensively studied. Samilu 
et al. (159) could show that tumor cells deficient in exosomes secretion produced enhanced 
T cell responses in vitro compared to the control counterpart [158]. They found that tumor-
derived EV induced immunosuppressive DC. This was due to abundant amounts of PGE2 in 
tumor-derived EV. PGE2 induced CD73 expression in DC accompanied with a higher activity 
of CD39. Both proteins led to increased hydrolysis of AMP into adenosine that inhibits T cells 
activity and supports tumor immune evasion.   
5.5  Myeloid cell predominantly take up tumor-derived EV 
We demonstrated in in vivo studies   that Ret-EV were taken up by MDSC. Here, we coupled 
GFP to the EV marker CD81. The CD81-GFP fusion protein was incorporated into EV during 
their biogenesis and released into the extracellular space. By the uptake of EV and this 
fusion GFP-CD81 protein respectively, the recipient cells became positive for GFP, allowing 
to analyze the recipient cells via flow cytometry. Confirming the in vitro results, we observed 
that GFP-positive MDSC in the TME showed a strong tendency to express more PD-L1 on 
their surface.  
Similar findings were reported by Ridder et al. [159] who used a sophisticated Cre-Lox 
system to track tumor-derived EV in vivo. The group demonstrated that functional Cre-mRNA 
is sorted into EV. After the release of those EV from the tumor cells, they are predominantly 
taken up by myeloid cells, preferentially by MDSC. Upon the uptake, the MDSC translated 
the Cre-mRNA into functional Cre-recombinase. The Cre-recombinase cut offs the Lox-sites 
on the DNA that allowed the reported gene to become transcribed. MDSC positive for the 
reported gene were analyzed via flow cytometry and they showed higher PD-L1 and 
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TGF-expression. Zomer et al. (160) demonstrated by using the same technique that EV 
interacted with different tumor cells in vivo [160]. The uptake of EV in this study led to more 
aggressive tumors by enhancing their migratory behavior and metastatic capacity. However, 
most studies did not track in vivo generated EV but rather in vitro isolated EV from various 
cell lines and injected those into wild type mice. It was shown that the administration of 
fluorescently labeled EV from metastatic cancer cell lines in vivo revealed that they were 
engulfed mainly by CD45+ immune cells in the BM [161]. Repeated injections of those EV 
increased the frequency of MDSC within the lung and liver. To prove that those effects were 
EV mediated, they administrated liposomes into naïve mice. Interestingly, liposomes were 
also taken up by the same type of cells that showed no immunosuppressive properties. Only 
EV-treated myeloid cells could inhibit T cell proliferation and reduce NK cell cytotoxicity. This 
comprehensive study clearly demonstrated a specific effect of tumor-derived EV in the 
conversion of IMC and expansion of MDSC.  
Plebanek et al. [162] observed that exogenously administrated fluorescently labeled EVs 
were also predominantly taken up by Ly6C+ myeloid cells in the BM. Depending on the origin 
of the EV, the Ly6C+ myeloid cells showed a different phenotype. EV from poorly metastatic 
cancer cells converted the myeloid cells into anti-tumorigenic patrolling monocytes, which 
assisted in the clearance of cancer cells at the pre-metastatic niche via the recruitment of NK 
cells. However, using EV from highly metastatic cancer cell lines led to larger tumor burden 
and increased formation of metastasis. However, in this study, the monocytes were not 
characterized when treated with EV from metastatic cell lines. Similar data were obtained 
with EV isolated from PDAC cell lines [163]. These EV carried macrophage migration 
inhibitory factor (MIF). By the uptake of MIF-containing EV, myeloid cells started to produce 
abundant amounts of TGF-, which in turn promoted an immunosuppressive 
microenvironment. Interestingly, the uptake of those EV by Kupffer cells in the liver also 
resulted in the secretion of TGF-, which induced the recruitment of BM-derived 
macrophages and neutrophils into the liver, which primed the formation of pre-metastatic 
niches in the liver (163). Knock-down of exosomal MIF resulted in a decrease of numbers of 
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macrophages and neutrophils in the liver and subsequently less formation of pre-metastatic 
niches. Further studies indicated that tumor cells reprogrammed BM microenvironment 
during tumor progression by releasing EV, which promoted the expansion of 
immunosuppressive cells in the BM.  
5.6  Tumor-derived EV induce inflammatory pathways in myeloid cells 
Immune cells developed various mechanisms to sense efficiently pathogens. TLR signaling, 
working through the NF-B pathway, allows immune cells to react quickly on invaders and to 
eliminate them [91]. However, incomplete clearance of the pathogens often results in chronic 
inflammation. Rudolf Virchow proposed already in 1863 that chronic irritation and 
inflammation causes cancer [164, 165]. In 1915, first experiments proved the hypothesis of 
Rudolf Virchow [165, 166]. Katsusaburo Yamagiwa, a student of Virchows, used coal tar on 
rabbit’s ears to induce chemical carcinogenesis. He observed atypical epithelial growth on 
the rabbit ears and announced:” Cancer is identified! Proudly I walk a few steps” [166]. 
Yamagiwa’s findings proved inflammation as a hallmark of cancer progression. In this work, 
we found that tumor-derived EV induced a chronic inflammatory environment. Ret-EV 
constantly activated the NF-B pathway in IMC. This activation was triggered by several 
TLR, with TLR4 as the predominant signaling pathway, leading to the expansion of 
immunosuppressive MDSC. 
Although TLR4 signaling in myeloid cells activates strong immune responses by inducing 
pro-inflammatory myeloid cells, mainly macrophages, it also causes collateral tissue damage 
if it is not properly regulated [167]. Therefore, feedback mechanisms were developed to 
regulate excessive immune activation [168]. One mechanisms is the decoyed activation of 
MDSC, which tempers the immune cells [167]. Arora et al. (169) demonstrated that LPS, a 
ligand of TLR4, can induce the expansion of MDSC in the lung [169]. They performed linage-
tracing experiments of BM progenitor cells in naïve mice. Upon LPS airway administration, 
the progenitors accumulated in the lung and showed an immunosuppressive phenotype. 
Blocking T cell effector function proved that those cells were MDSC. Further studies by Poe 
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et al. (170) demonstrated that MDSC accumulated in the lung upon LPS administration [170]. 
This accumulation was delayed compared to other myeloid cell subsets, but after three days, 
MDSC were the predominant myeloid population within the lung. The enriched lung MDSC 
suppressed DC ability to promote Th2 responses. Furthermore, these MDSC engulfed 
apoptotic neutrophils to restore lung homeostasis.  
Besides LPS, further TLR4 ligands were found to induce MDSC function and expansion. 
S100A9 was found to act through the NF-B pathway by triggering TLR4 [101]. Later on, 
Cheng et al. (171) found that S100A9 was a potent inducer of MDSC expansion [171]. 
S100A9 expression was up regulated through the STAT3 pathways in myeloid cells and 
acted as an inflammatory cytokine, blocking the differentiation of DC and promoting the 
differentiation and expansion of MDSC. Furthermore, it was shown that S100A9 and its 
dimerization partner S100A8 induced the expression of iNOS in macrophages in a 
NF-B/TLR4 dependent pathway [172]. In addition to S100A9, high mobility group box 1 
(HMGB1) was found to be a ligand for TLR4 [173]. It binds to TLR4 via the A-box domain 
with high affinity, which was proved by surface plasmon resonance [173]. In general, HMGB1 
is secreted by macrophages and also by necrotic cells [104]. This results in elevated HMGB1 
level in plasma of cancer patients. HMGB1 was described to induce MDSC via the TLR4 
signaling pathway (104). Here, IMC were cultured in vitro with either GM-CSF or GM-CSF 
together with HMGB1.  After 4 days of culture, IMC become more immunosuppressive when 
cultured with both stimuli. Further studies proved the importance of HMGB1 on MDSC 
biology and tumor growth [174-176]. The correlation of tumor growth, HMGB1 and MDSC 
were proved by using a mouse model for renal cell carcinoma [177]. Here, tumor-bearing 
mice were treated with neutralizing antibodies against HMGB1 that resulted in tumor growth 
inhibition. Interestingly, when MDSC were depleted in the same experimental set up, the 
HMGB1 blocking showed no effect any more on tumor growth, proving the importance of 
HMGB1 in MDSC biology. 
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Although the TLR4 signal cascade was evolved to protect the host against gram-negative 
bacteria, many tumor cells use this particular receptor for immune evasion. There is a 
growing body of evidence that tumors induce chronic inflammation through TLR4 signaling. 
Lee et al. (178) performed  tumor growth experiments in wild type and TLR4-deficient mice 
that proved this hypothesis [178]. TLR4-deficient mice showed a reduced growth of several 
tumor cell lines studied due to TLR4 signaling in TAM. TAM produced pro-inflammatory 
cytokines upon TLR4 signaling, which resulted in chronic inflammation. By adoptive transfer 
of wild type TAMs into TLR4 deficient mice, the beneficial effects could be abrogated, 
indicating that TAMs are the main reason for the TLR4-dependent tumor growth [178]. 
Interestingly, the TLR4 was shown to be triggered by HSP70 and HSP90. By blocking both 
HSP with neutralizing antibodies in tumor-bearing mice, the production of inflammatory 
mediators, especially VEGF and TNF-was decreased. 
5.7  Tumor-derived EV induce inflammatory pathways in myeloid cells 
In this work, we found that TLR4 was a predominant inducer of MDSC after Ret-EV 
treatment. However, we could also identify that TLR2 and TLR7 promoted 
immunosuppressive properties. It seems that tumor cells use a broad spectrum of TLR to 
induce immunosuppression. Haderk et al. [128]  found that TLR7 was the dominant signaling 
pathway to induce PD-L1 on monocytes. In addition, Chalmin et al. [126] found that tumor-
derived EV promoted MDSC expansion by the TLR2 signaling cascade. Although many 
studies used TLR agonist to promote anti-tumor responses, the promotion of 
immunosuppression was often ignored.  
Preclinical studies, using the TLR2 agonist Pam2/CSK4, could demonstrate that tumor 
growth was accelerated in mice due to the increase of monocytic MDSC with enhanced 
immunosuppressive properties [179]. Similar studies were performed by using lipopeptides to 
induce TLR2/6 signaling in skin-bacteria infected mice [180]. The authors showed that the 
immune response was decreased due to the expansion of MDSC, which was induced by 
TLR2/6 stimulated secretion of IL-6 by skin resident cells. However, other studies described 
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beneficial effects of TLR agonist as adjuvants for immunotherapy by inhibiting MDSC 
expansion. Wang et al. (181) used TLR7/8 agonist to convert human monocytic MDSC into 
tumoricidal M1-like macrophages [181]. Another study applied Poly (I:C) as an adjuvant for 
immunotherapy of tumor-bearing mice  and showed a reduction of tumor growth [182]. The 
reason for this was the modulation of the immunosuppressive properties of MDSC and their 
reduced frequency. It seems that TLR agonist acts as a two-sided sword. On one hand, they 
can induce immune responses by activating myeloid cells, and on the other hand they 
stimulate a time-delayed immunosuppression to prevent excessive immune responses. 
5.8  HSP are drivers of immunosuppression 
In the last years, many studies described that subtypes of HSP60, HSP70, HSP90 and 
HSP110 acted in a TLR dependent manner, [126, 130-133, 183, 184]. Recently, Hong et al. 
(185) have proved that gp96, an isoform of HSP90, interacted with TLR2 and TLR4 [185]. 
They used a comprehensive interactome study to map all ligands for gp96, where they found 
511 clients, including TLR2 and TLR4. Besides stimulating TLR signaling HSP were 
associated with MDSC biology. In vitro studies by Janssen et al. (186) demonstrated  the 
capacity of HSP70 and HSP90 to convert human monocytes into immunosuppressive MDSC 
[186]. They treated several melanoma cell lines with blocking antibodies against HSP70 and 
HSP90 followed by their co-culture with monocytes. Interestingly, HSP70 and HSP90 treated 
melanoma cells were less effective in converting monocytes into MDSC compared to isotype 
treated control. The efficacy of reprogramming was measured by T cell suppression. In vivo 
experiments by Roa et al. (187) showed a therapeutic potential of HSP90 [187]. 17-
Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an inhibitor of HSP90 
was used to treat mice with MCA205 sarcoma. Upon administration of 17-DMAG treated 
MCA205 sarcoma cells into mice, tumor growth was significantly reduced compared to 
untreated control that was accompanied by enhanced recognition of tumors by CD8+ T cells 
and reduced frequencies of MDSC in the TME. Furthermore, using 17-DMAG as an immune 
adjuvant together with adoptive T cell transfer into tumor-bearing mice resulted in better 
immunotherapeutic effects compared to adoptive T cell transfer alone. Combined treatment 
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led to the destruction. HSP were also shown to block the differentiation of BM cells into fully 
matured DCs [134, 188]. Motta et al. used recombinant HSP70 to block the differentiation of 
BM precursors into mature DC [188]. The treated cells showed a regulatory phenotype due 
to a secretion high IL-10 levels Moreover, theses DC became suppressive, which was shown 
by T cell proliferation assays in vitro. Another group that performed similar experiments 
confirmed these findings [134]. Taken together, these data indicates the immunosuppressive 
properties of HSP that block the differentiation of naïve BM precursor cells into mature 
immune cells and direct them to immunosuppressive cells.  
5.9  Conclusion 
The generation and activation of MDSC is a limiting step for successful immunotherapeutic 
approaches. Therefore, it is crucial to find targets, helping to reduce MDSC activity and 
improve immunotherapies.  
In this study, we unveil a new mechanism of MDSC induction by tumor cells. Our data 
highlight the molecular mechanism of the conversion of murine IMC into MDSC by 
melanoma-derived EV. We could prove that melanoma cells secrete EV with HSP86 on their 
surface. The melanoma-derived EV were taken up by myeloid cells and induced PD-L1 
expression on their surface. The PD-L1 expression is triggered by the HSP86-TLR4 axis, 
resulting in NF-B signaling. Furthermore, we could demonstrate that EV-treated IMC 
acquired immunosuppressive features showed by the inhibition of T cell proliferation and 
IFN- secretion. Blocking PD-L1 on IMC resulted in the abrogation of immunosuppressive 
capacity of EV-educated cells, suggesting a critical role of this pathway in the acquisition of 
immunosuppressive properties. This study delivers a new target for future immunotherapies. 
Besides using checkpoint inhibitors or adoptive T cell transfer, we suggest to use inhibitors of 
vesicular HSP86 to enhance the efficiency of tumor immunotherapy. 
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TBK1 Tank-binding kinase 1 
TGF Transforming growth factor 
TIR Toll/interleukin-1 receptor 
TLR Toll-like receptors 
TME Tumor microenvironment 
TNF Tumor necrosis factor 
TRAF TNF receptor associated factor 
Treg Regulator CD4+ T cells 
TRIF TIR-domain-containing adapter-inducing interferon-β 
T-VEC Talimogen laherparepvec 
V  
VEGF Vascular endothelial growth factor 
Z  
ZAP70 Zeta-chain-associated protein kinase 70 
 
  
List of Figures 
113 
 
List of Figures 
Figure 1: The concept of Immunoediting. Tumor cells and immune cells are in constant 
interaction that is divided in three phases. In the “Elimination” phase, immune cells attack 
and kill the tumor cells. A high immunological pressure on tumor cells characterizes the 
“Equilibrium” phase. However, in this phase some tumor cells survive due to favoring 
mutations. In the “Escape” phase, tumor cells acquired properties that hide them from our 
immune system. Figure was adopted from Kalbasi et al., 2013 (38) ........................................... 6 
Figure 2: Biology of MDSC. MDSC arise from IMC in the bone marrow due to constant but 
weak activation by cytokines. MDSC leave the BM and migrate to the TME following the CCL 
and CXCL gradient released by tumor and immune cells. Within the TME, MDSC support 
tumor growth especially by suppressing T cells. Here fore, they use various mechanisms. 
Figure was adopted from Fleming et al., 2018 (46) ........................................................................ 8 
Figure 3: Subsets of EV. EV consists of three different subsets. The smallest subsets are 
the exosomes, which are generated within MVB. By the fusion of the MVB with the plasma 
membrane, exosomes gets released into the extracellular space. The second subsets are 
the microvesicles. The outward budding of the plasma membrane creates them. The biggest 
subset is called apoptotic bodies. They are produced by cells undergoing apoptosis. Figure 
was adopted from György et al., 2011 (77). ................................................................................... 13 
Figure 4: Signaling pathway in TLR. TLR recognizes specific PAMP and DAMP from 
pathogens or Host cell. TLR3, TLR7, TLR8 and TLR9 are found on endosomal/lysosomal 
membrane, whereas the others are localized on the plasma membrane. Upon binding to its 
respective ligand, TLR recruit adaptor protein MyD88 or TRIF. MyD88 recruits IRAK4. 
Through the interaction of IRAK4 and TLR, IRAK1 becomes phosphorylated and binds 
TRAF6. TRAF6 activates NF-B through phosphorylation of its inhibitor. Furthermore, TRAF6 
activates MAPK signaling that result in activated JNK and p38 pathways. These transcription 
factors foster the transcription of inflammatory genes and cytokines. In addition, adaptor 
molecule TRIF recruits RIP1, which in turn activates TRAF3 that promotes the recruiting of 
IB kinase (IKK) / Tank-binding kinase 1 (TBK1), leading to the phosphorylation of IRF3. 
IRF transmigrate to the nucleus and activates Type-I IFN and IFN-induced genes(106) ....... 19 
Figure 5: The Hsp90 chaperone complex. Freshly translated peptides are linked to the 
HSP70/HSP40 complex by hydrophobic residues. The Hsp70/Hsp40 complex carries the 
client to HSP90 dimers. HOP supports the binding of Hsp70/Hsp40 to Hsp90. HOP also 
facilitates the transfer of the client to Hsp90. Exchange of ADP to ATP leads to the 
dissociation of the Hsp70/Hsp40 complex and close the Hsp90 complex with the client. P23 
stabilize the complex. Upon ATP hydrolysis p23 and the client dissociates from the Hsp90 
complex as fully maturated and folded protein(109) ..................................................................... 22 
Figure 6: Isolation of Ret-EV. Ret-EV containing supernatant was sterile filtered with 0.22 
µm filters. Afterwards, sterile supernatant was concentrated by 100 kDA size exclusion 
filtration. The concentrate was ultra-centrifuged by 100.000 g ultracentrifugation at 4°C for 90 
min. EV-containing Pellet was re-suspended in sterile PBS. ...................................................... 34 
Figure 7:Gating strategy of EV-coupled on latex beads. ....................................................... 37 
Figure 8: Gating strategy of isolated IMC .................................................................................. 43 
Figure 9: Gating strategy for BM cells ........................................................................................ 45 
Figure 10: Gating strategy of tumor tissue ................................................................................ 46 
Figure 11: Gating strategy for proliferating T cells. ................................................................ 50 
Figure 12: Characterization of Ret-EV. Ret-EV were isolated by filtration and 
ultracentrifugation. A) Nanoparticle tracking analysis of Ret-EV. B) Representative sample 
showing the expression of EV- markers (CD9, CD81 and ALIX) detected by Western blot 
List of Figures 
114 
 
analysis. The ER marker calreticulin was used as a negative control. C) EV marker CD81 
detected by immunogold labeling and electron microscopy. ....................................................... 55 
Figure 13: Uptake of Ret-EV by myeloid cells. Ret-EV were labeled with CFSE and 
incubated with murine MSC-1 cells or BM-derived IMC for 16 h. As a control, we incubated 
CFSE in PBS with the same concentration as Ret-EV. After CFSE labeling Ret-EV and 
control were ultra-centrifuged to wash out residual CFSE. A) The internalization of CFSE-
Ret-EV by MSC-1 cells was measured by fluorescent confocal microscopy B) and by IMC via 
flow cytometry. .................................................................................................................................... 56 
Figure 14: IMC show altered miRNA expression profile after Ret-EV treatment. IMC 
isolated from the BM of wild type C57BL/6 mice were treated with Ret-EV or PBS for 3 h. 
After 3 h whole RNA content was isolated and miRNA microarray was performed using 
Agilent chip. A) Heat-map analysis and B) Volcano-plot showed different miRNA expression 
profile of IMC treated with either Ret-EV or PBS. .......................................................................... 57 
Figure 15: Ret-EV-mediated upregulation of miRNA and cytokines important for MDSC 
biology. IMC isolated from the BM of wild type C57BL/6 mice were treated for 3 h with Ret-
EV. Afterwards whole RNA was isolated and converted into cDNA. RT-PCR analysis of 
respective A) miRNA (n=2) and B) cytokines show relative expression level of PBS and Ret-
EV-treated IMC (mean ± SEM; n=3). *p < 0.05, **p < 0.01. ........................................................ 59 
Figure 16: Well-known immunosuppressive mediators are unchanged in IMC upon 
Ret-EV treatment. IMC isolated from the BM of wild type C57BL/6 mice were treated with 
Ret-EV for 16 h. Afterwards IMC were stained for flow cytometry A-C) MFI of ROS, NO and 
Arg-1 from whole IMC population is shown. D) Represents Arg-1 activity in Units/l measured 
by photometrical assay to measure Arg-1 activity. (mean ± SEM; n=3) .................................... 60 
Figure 17: PD-L1 expression is up regulated on IMC after Ret-EV treatment. IMC 
isolated from the BM of wild type C57BL/6 mice were treated with Ret-EV for 16 h. A) 
Representative dot plots of PD-L1 expression on IMC before and after 16 h Ret-EV treatment 
(including FMO control of Ret-EV treated IMC). PD-L1 expression on IMC with Ret-EV or EV 
isolated from cardiac fibroblasts (Fibro-EV) was evaluated by flow cytometry. B) represents 
the percentage of PD-L1+ IMC within total IMC and C) the level of PD-L1 expression 
measured as mean median fluorescence intensity (MFI) D) Representative Western blot 
analysis showing PD-L1 expression in IMC upon Ret-EV treatment. (mean ± SEM; n=3). *p < 
0.05, **p < 0.01, ***p < 0.001. ........................................................................................................... 61 
Figure 18: Trans-well studies confirm the Ret-EV-mediated PD-L1 up regulation on 
IMC. A) Ret cells or fibroblasts were co-incubated with IMC for 24 h using a 0.4 µm trans-
well system. The analysis of PD-L1 expression on IMC was performed by flow cytometry. B) 
Data are shown as the percentage of PD-L1+ IMC among total IMC and C) the level of PD-L1 
expression as MFI (mean ± SEM; n=4) *p < 0.05, **p < 0.01, ***p < 0.001. ............................. 62 
Figure 19: Ret-EV mediated upregulation occurs in vivo. A) Demonstrates a schematic 
overview of the experiment. GFP is linked to CD81 that is incorporated into EV. EV are 
released by tumor cells and recipient cells take up the GFP-labeled tumor-derived EV. Ret 
cells were transduced with vector expressing CD81 linked to GFP or control vector. B-C) 
Transduced cells were injected subcutaneously into C57BL/6 mice. Upon 14 days of tumor 
growth, mice were sacrificed and single cell suspension from tumor tissue was made 
followed by staining for MDSC. Stained samples were measured by flow cytometry. B) 
Representative dot plots for GFP expression in tumor-infiltrating CD11b+Gr1+ are shown. C) 
Expression of PD-L1 on GFP+ MDSC was presented as MFI (mean ± SEM; n=3). ................ 63 
Figure 20: EV-treated IMC show immunosuppressive capacity mediated by PD-L1. IMC 
isolated from the BM of C57BL/6 mice were incubated with Ret-EV for 16 h. After washing 
out the rest of EV, cells were treated with PD-L1 neutralizing or isotype control mAbs (Iso) for 
15 min followed by the co-incubation with normal spleen CD8+ T cells labeled with CFSE and 
stimulated with anti-CD3/CD28 Dynabeads for 72 h. T cell proliferation was evaluated by 
List of Figures 
115 
 
CFSE dilution by flow cytometry. A) Inhibition of CD8+ T cell proliferation by EV-treated IMC 
at indicated IMC:T cell ratio. Data are presented as the percentage of divided T cells (mean ± 
SEM; n=6). B) Proliferation and C)  IFN-secretion of stimulated CD8+ T cells upon blocking 
PD-L1 expression on IMC (IMC:T cell ratio=1:1;  mean ± SEM; n=3). *p < 0.05, **p < 0.01. 65 
Figure 21: PD-L1 is not transferred via vesicular transport. A) Representative Western 
blot of PD-L1 in Ret-lysate and Ret-EV. B) MSC-2 and MSC-I cells were treated with Ret-EV 
and PD-L1 expression was determined after 16 h via Western blot. C) MSC-2 cells were 
treated with the RNA synthesis inhibitor actinomycin-D followed by Ret-EV incubation for 16 
h. Ret cells were lysed and PD-L1 expression was determined via Western blot analysis. ... 67 
Figure 22: PD-L1 up-regulation induced by Ret-EV is mediated by NF-B activation. A) 
Time dependent accumulation of pNF-B in MSC-2 cells under the treatment with Ret-EV 
detected by Western blot. B) MSC-2 cells were treated with the NF-B inhibitor Bay followed 
by Ret-EV incubation followed by flow cytometry. Results are presented as the level of PD-1 
expression on MSC-2 measured as MFI (mean ± SEM; n=4). C) IMC isolated from the BM of 
C57BL/6 mice were incubated with Ret-EV for 16 h and pNF-B was stained and measured 
by flow cytometry. Results are presented as MFI of whole IMC population. (mean ± SEM; 
n=4) *p < 0.05, **p < 0.01. ................................................................................................................. 68 
Figure 23: TLR agonist stimulate activation of NF-B in MSC cell lines. MSC-1 and 
MSC-2 cells were treated with respective TLR agonist for indicated time. MSC cells were 
lysed afterwards and pNF-B was detected by Western blot analysis. ..................................... 70 
Figure 24: Ret-EV induced PD-L1 upregulation is mediated by the MyD88 dependent 
TLR pathway. IMC were isolated from the BM of mice deficient for MyD88 or for MyD88 and 
TRIF followed by incubation for 16 h followed by flow cytometry. A) Data are shown as the 
percentage of PD-L1+ IMC within total IMC or B) the level of PD-L1 expression as MFI 
(mean; n=2). ........................................................................................................................................ 71 
Figure 25: Ret-EV mediated PD-L1 upregulation is triggered mostly by TLR4 signaling.  
A) IMC were isolated from the BM of wild type and the intensity of indicated TLR was 
measured via flow cytometry B) IMC were treated with respective TLR agonist and PD-L1 
upregulation was  measured via flow cytometry. PD-L1 expression is presented as the 
percentage of PD-L1+ IMC within total IMC C) IMC were isolated from the BM of wild type 
and TLR-deficient C57BL/6 mice and treated with Ret-EVs for 16 h followed by flow 
cytometry. C) PD-L1 expression is presented as the percentage of PD-L1+ IMC within total 
IMC or D)  as the level of PD-1 expression on IMC measured as MFI (mean ± SEM; n=4). E) 
Expression of PD-L1 in wild type and Tlr4-/- IMC measured by RT-PCR and normalized to 18s 
RNA F) Inhibition of CD8+ T cell proliferation by wild type and TLR4-/- IMC treated with Ret-
EV (IMC:T cell ratio = 1:1??). Data are presented as the percentage of divided T cells (mean 
± SEM; n=6). *p < 0.05, **p < 0.01. ................................................................................................. 73 
Figure 26: Educating mice with Ret-EV promotes tumor growth in wild type mice but 
not in TLR4-deficient mice. Ret-EV or PBS were injected each second day into wild type or 
Tlr4-/- mice. On day 5, Ret cells were injected subcutaneously into the flank. A) Tumor 
progression was monitored for 14 day and B) tumor was weight on day 14 after mice were 
sacrificed (mean ± SEM; n=3) *p < 0.05. ........................................................................................ 74 
Figure 27: Ret-EV carry high amounts of HSP86 and HSP72.  A) Different batches of Ret-
EV were lysed and indicated proteins were analyzed by Western blot. B) Ret-EV were 
coupled onto latex beads and stained for indicated HSP. HSP expression level was 
measured via flow cytometry. Black line indicates the secondary antibody control and blue - 
the expression of indicated HSP. ..................................................................................................... 75 
Figure 28: HSP86 is critical for Ret-EV mediated PD-L1 upregulation on IMC. A) Ret 
cells were treated with the indicated concentrations of KNK-437. After 24 h Ret cells were 
lysed and proteins were isolated. The expression of HSP86 in cell lysates was analyzed by 
Western blot. B-C) NTA of KNK-EV and Ret-EV showing the size distribution and 
Acknowledgements 
116 
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